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ABSTRACT
Obstructive sleep apnoea (OSA) is the most common sleep-related breathing 
disorder and is characterized by recurrent episodes of complete or partial 
obstruction of the upper airway leading to reduced or absent breathing during 
sleep. The prevalence of OSA in adults is approximately 25% in developed 
countries. The main known risk factors for OSA are increasing age, male sex, 
menopause, obesity and certain craniofacial structures and anomalies. The role of 
OSA on the risk of adverse cardiovascular outcomes has been widely studied, and 
mechanisms linking OSA to its cardiometabolic correlates through intermittent 
hypoxia, oxidative stress and increasing sympathetic activity are also recognized. 
Despite the fact that the epidemiology of OSA has been under research for decades, 
the genetics behind OSA risk have remained mainly unstudied. However, family 
studies have shown that family members are at a 2–4-fold greater risk of having 
OSA if there are OSA patients in the family. It is estimated that 40% of the variation 
in the apnoea-hypopnoea-index (AHI) is genetically regulated. Previous genome-
wide-association studies (GWASes) have addressed OSA severity based on AHI 
or respiratory event duration, but case-control studies have not been previously 
published.
The World Health Organization (WHO) announced COVID-19 as a pandemic 
in March 2020. Patients with COVID-19 have a wide range of symptoms ranging 
from mild flu-like symptoms to severe illness. The first studies regarding COVID-19 
revealed that male gender, higher age, obesity and diabetes are risk factors for the 
severe form of the disease, indicating that OSA and COVID-19 share numerous 
common risk factors and comorbidities. Furthermore, studies have suggested that 
OSA is a risk factor for the severe form of COVID-19. 
We estimated the role of OSA in major cardiometabolic disease by utilizing 
population-based cohorts, including FINRISK, Health 2000 and a subset of 
the Botnia Study, and registry information to longitudinally assess OSA risk 
in the Finnish population. Our data consisted of 36,963 individuals with over 
500,000 person-years and up to twenty-five years of follow-up data, including 
1,568 OSA patients. Using Cox-proportional hazards models, our results revealed 
that OSA is associated with a 1.36-fold increased risk for coronary heart disease 
(CHD), including a 2.01-fold increased risk in women independent of other 
potential confounding factors. Similarly, type 2 diabetes (T2D) correlated with 
OSA independent of obesity status and revealed a 1.48-fold increased risk. This 
association was also significant in women, showing a 1.63-fold increased risk. 
The risk of diabetic kidney disease (DKD) was increased by 1.75-fold in 
patients with OSA among the T2D study sample. All-cause mortality was increased 
in individuals with both OSA and T2D by 35%. 
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To study the genetic burden for the risk of OSA we proceeded to identify 
genetic loci associated with OSA risk and aimed to test if OSA and its comorbidities 
share a common genetic basis. To elucidate these aims, data from the FinnGen 
project was used. The FinnGen project combines patient genotype data and 
nationwide registry information with anthropometric measurements, such as body 
mass index (BMI) and smoking. Using this information, we conducted the first 
large-scale case-control GWAS of OSA with 217,955 individuals including 16,761 
OSA patients. We identified five genetic loci associated with OSA, highlighting the 
importance of genetic variation on OSA predisposition. This was further supported 
by our single nucleotide polymorphism (SNP)-based heritability estimates. We also 
showed the causal relationship between obesity and OSA by utilizing Mendelian 
randomization (MR). Although BMI is the major risk factor, we were also able to 
find a BMI-independent genetic locus for OSA that is associated with antidepressant 
purchases. However, we could not replicate this locus in independent cohorts. In 
addition, we found strong genetic correlations between OSA and its comorbidities 
including BMI, hypertension, T2D, CHD, stroke, depression, hypothyroidism, 
asthma and inflammatory rheumatic diseases (IRD) in addition to other sleep 
traits such as sleepiness and sleep efficiency. These findings implicate OSA as a 
heterogenic disease with several distinct comorbidities, which would be beneficial 
to consider when treating patients with OSA. 
When COVID-19 emerged, it became apparent that the risk factors for the severe 
form of the disease showed similarities with OSA risk factors and comorbidities. 
Our aim was to study if OSA patients have a higher risk for hospitalisation due 
to COVID-19 disease in addition to other potential confounding factors, and if 
OSA associates with an increased risk of contracting COVID-19.  We studied 445 
individuals with COVID-19 including thirty-eight OSA patients extracted from 
the FinnGen project data (N=260,405). Of the OSA patients, nineteen required 
hospital treatment due to COVID-19 infection.  OSA was associated with a 2.93-fold 
increased risk of COVID-19 hospitalisation independent of age, sex, BMI and other 
comorbidities. The results were further confirmed in a meta-analysis including 
15,835 individuals. Importantly, treatment information regarding OSA was also 
collected and suggested that moderate and severe OSA is a risk factor for severe 
COVID-19 even if the OSA is well managed. 
This thesis concentrates on studying OSA as a risk factor for cardiometabolic 
comorbidities, the genetic variation between OSA and non-OSA individuals and 
whether OSA creates an elevated risk for severe COVID-19 disease. These studies 
were conducted by utilizing large and accurate data sets with an epidemiological 
and longitudinal ascertainment, and by applying modern genetic methods to show 




Obstruktiivisella uniapnealla (uniapnea) tarkoitetaan toistuvia unenaikaisia vä-
hintään kymmenen sekunnin mittaisia hengityskatkoksia (apnea) tai hengityksen 
vaimentumia (hypopnea), jotka johtuvat ylähengitysteiden ahtautumisesta. Uniap-
nean prevalenssin on arvioitu olevan jopa 25 % aikuisväestössä. Sen tunnetuim-
mat riskitekijät ovat korkea ikä, miessukupuoli, vaihdevuosi-ikä, ylipaino ja tietyt 
kraniofakiaaliset piirteet, kuten pieni tai takana sijaitseva alaleuka. Uniapnean 
ja sydän- ja verisuonitautien yhteyttä on tutkittu laajasti epidemiologisin tutki-
musmenetelmin, ja niitä yhdistävät mekanismit, kuten jaksottainen hapenpuute, 
oksidatiivinen stressi ja uniapnean vaikutukset sympaattisen hermoston aktiivi-
suuden lisääntymiseen, tunnetaan. Epidemiologisista tutkimuksista ja tuloksista 
huolimatta uniapean genetiikan tutkimus on ollut melko vähäistä. Viitteitä on saa-
tu siitä, että uniapneapotilaan perheenjäsenellä on 2–4-kertainen riski sairastua 
uniapneaan ja lisäksi on arvioitu, että 40 % apnea-hypopnea-indeksin variaatiosta 
on geneettisesti säädelty. Genominlaajuinen assosiaatioanalyysi on tuonut uuden 
menetelmän analysoida yleisiä kompleksisia tauteja, kuten uniapneaa. Näissä ai-
emmissa uniapneaa koskevissa tutkimuksissa on tutkittu taudin vaikeusastetta 
ja hengitystapahtuman kestoa. Kuitenkaan tapaus-verrokki -tutkimusta koskien 
uniapneaa ei ole aiemmin julkaistu. 
Joulukuussa 2019 Kiinan Wuhanista alkoi epidemia, jonka aiheuttajana on 
ihmiselle uusi koronavirus. Sen aiheuttama tauti on viralliselta nimeltään CO-
VID-19. Virus levisi nopeasti maailmanlaajuisesti ja maaliskuussa 2020 Maail-
man terveysjärjestö WHO julisti koronavirusepidemian pandemiaksi. COVID-19 
aiheuttaa useimmille lieväoireisen hengitystieinfektion, mutta osalle potilaista 
infektio voi olla jopa henkeä uhkaava. Vakavan COVID-19 infektion riskitekijöihin 
kuuluvat mm. korkea ikä, ylipaino ja diabetes. Näin ollen COVID-19 ja uniapnea 
jakavat suuren määrän samoja riskitekijöitä ja liitännäissairauksia. Lisäksi on 
havaittu, että uniapnea voi lisätä riskiä vakalle COVID-19-infektiolle.
Arvioimme uniapnean aiheuttamaa riskiä koronaaritaudille, tyypin 2 diabe-
tekselle, diabeteskomplikaatioille ja kuolleisuudelle hyödyntämällä FINRISKI ja 
Terveys 2000 kohortteja sekä osajoukkoa Botnia-tutkimuksesta. Tutkimuksem-
me sisälsi 36 963 henkilöä ja se kattoi yli 500 000 henkilövuotta yltäen jopa yli 
25-vuoden seuranta-aikaan. Käyttämällä Cox-elinaikamallia havaitsimme, että 
uniapnea liittyy koronaaritaudin riskiin 1.36-kertaisesti riippumatta muista ris-
kitekijöistä, kuten verenpainetaudista tai painoindeksistä. Tämä yhteys nähtiin 
myös naisilla, joilla yhteys riskiin nousi 2.01-kertaiseksi. Vastaavasti uniapnean 
havaittiin olevan ylipainosta riippumaton riskitekijä tyypin 2 diabetekselle liittyen 
riskiin 1.48-kertaisesti. Vaikutus havaittiin myös naisilla, joilla uniapnea yhdistyi 
1.63-kertaiseen riskiin. Lisäksi uniapnea assosioitui kohonneeseen riskiin dia-
beetikkojen munuaissairauksille 1.75-kertaisesti ja uniapnean nähtiin lisäävän 
kuolleisuutta 35 % tyypin 2 diabeetikoilla. 
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Tutkiaksemme uniapnean genetiikkaa hyödynsimme FinnGen-aineistoa, 
joka yhdistää genomitietoja kansallisiin terveysrekistereihin. Tarkastelimme 
uniapneaa käyttämällä genominlaajuista assosiaatioanalyysiä sisältäen 217 955 
henkilöä, joista 16 761:lla oli uniapneadiagnoosi. Löysimme viisi uniapneariskiin 
assosioituvaa lokusta. Tämä tutkimus korostaa geneettisen variaation merkitystä 
uniapnealle altistumisessa, jota heritabiliteettilöydöksemme vahvistaa. Näytimme 
lisäksi mendeliaanisen randomisaation avulla, että ylipainon ja uniapnean välillä 
on kausaalinen suhde, joka on ollut nähtävissä epidemiologisissa tutkimuksissa. 
Huolimatta siitä, että ylipaino on uniapnean tärkein riskitekijä, löysimme pai-
noindeksistä riippumattoman lokuksen, joka oli spesifi uniapneadiagnoosille, ja 
joka yhdistyi masennuslääkeostoihin. Tätä tulosta emme kuitenkaan onnistuneet 
toistamaan itsenäisissä aineistoissa. Havaitsimme voimakkaita geneettisiä korre-
laatioita uniapnean ja sen liitännäissairauksien, kuten verenpainetaudin, tyypin 2 
diabeteksen, koronaaritaudin, depression, kilpirauhasen vajaatoiminnan, astman 
ja inflammatoristen reumasairauksien välillä. Lisäksi geneettiset korrelaatiot oli-
vat vahvoja uniapean ja päiväväsymyksen sekä unen tehokkuuden välillä. Nämä 
havainnot viittaavat siihen, että uniapnea on heterogeeninen sairaus, johon liittyy 
useita eri tauteja, jotka tulisi huomioida uniapneapotilaita hoidettaessa. 
Tarkastelimme lisäksi uniapnean aiheauttamaa riskiä vakavalle COVID-
19-infektiolle ja mahdollisesti uniapneapotilaiden suurentunutta riskiä saada in-
fektio. Hyödyntämällä FinnGen-kohorttia (N=260 405) aineistomme sisälsi 445 
COVID-19 positiivista henkilöä, joista 38:lla oli lisäksi uniapneadiagnoosi. Heistä 
19 tarvitsi sairaalahoitoa COVID-19 aiheuttaman infektion vuoksi. Uniapnea liit-
tyi 2.93-kertaiseen riskiin vakavalle infektiolle riippumatta muista riskitekijöistä, 
kuten iäistä, sukupuolesta, painoindeksistä, verenpainetaudista, tyypin 2 diabe-
teksesta, koronaaritaudista, keuhkoahtaumataudista ja astmasta. Lisäksi teimme 
meta-analyysin, joka sisälsi 15 835 COVID-19 positiiviseksi testattua henkilöä 
vahvistaen tietoutta uniapnean aiheuttamasta kohonneesta riskistä. Keräsimme 
uniapneapotilaiden hoitotietoja ennen sairastumista COVID-19-infektioon ja ha-
vaitsimme, että vaikka suurin osa uniapneapotilaista oli hoidettu, vaativat he silti 
sairaalahoitoa. Tämä antaa viitteitä siitä, että keskivaikea ja vaikea uniapnea on 
hoidettunakin riskitekijä vakavalle COVID-19-infektiolle. 
Tämä väitöskirja tutkii uniapnean yhteyttä kardiometabolisten sairauksien 
ilmaantuvuuteen ja niiden riskitekijöihin. Samalla se selvittää geneettistä vaihtelua 
uniapneapotilaiden ja ei-uniapneapotilaiden välillä tarkastellen lisäksi uniapnean 
geneettistä yhteyttä sen liitännäissairauksiin hyödyntämällä laajoja kansallisia 
aineistoja epidemiologisesta ja geneettisestä näkökulmasta luoden katsauksen 
uniapneasta suomalaisessa väestössä. Tutkimuksissa on hyödynnetty niin pitkit-
täistutkimukseen soveltuvia kuin uusimpia geneettiseen laskentaan kehiteltyjä 
menetelmiä. Lisäksi keskivaikean ja vaikean uniapnean yhteys COVID-19-infetion 
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1 INTRODUCTION 
Sleep apnoea is a common sleep-related breathing disorder causing reduced or 
absent breathing during sleep. Sleep apnoea can be divided into three groups: 
obstructive sleep apnoea (OSA), central sleep apnoea (CSA) and mixed sleep apnoea, 
which is a combination of both OSA and CSA. OSA represents the majority of cases 
of sleep apnoea (1, 2) and is a widely prevalent disease especially in developed 
countries with an estimated prevalence of approximately 25% among the general 
population (1). The prevalence of OSA is highly age dependent, increasing up to 
40% among individuals aged 50 to 70 years (3). 
The main risk factors for OSA include older age, male sex, menopause, 
obesity and craniofacial structure variations and anomalies (4). OSA has been 
established as a risk factor for cardiovascular diseases through sympathetic 
activation, oxidative stress, and intermittent hypoxia (5-7). 
Genetic factors contribute to the main risk factors for OSA, such as obesity 
and craniofacial structures (8, 9). However, the genetic association to OSA itself has 
not been adequately studied, although for example family members are estimated 
to have a 2–4-fold greater risk of having OSA, indicating a genetic predisposition 
(10). Therefore, the genetic risk factors for OSA remain an important subject of 
investigation. 
Genome-wide association studies (GWASes) concerning OSA severity and 
respiratory event duration exist (11-13), but GWAS on apnoea risk comparing apnoea 
patients and healthy controls have not been published until now. Biobanks and 
longitudinally-collected registry-based data have created a unique environment 
to investigate common diseases, such OSA, over a patient’s lifespan. The FinnGen 
biobank project combines genome and registry data with anthropometric 
measurements such as body mass index (BMI) and smoking, providing an excellent 
resource for the study of common complex diseases such as OSA. 
COVID-19, which is caused by the virus severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), was first identified in December 2019 in Wuhan, 
China. SARS-CoV-2 quickly spread worldwide, and the new virus was declared a 
pandemic in March 2020 by the World Health Organisation (WHO) (14). The risk 
of developing a severe COVID-19 illness is increased by pre-existing conditions 
that significantly impair the functioning of the lungs, heart, or immune system 
(15). Severe COVID-19 and OSA also share multiple common risk factors and 
comorbidities, such as higher age, obesity, and diabetes. Furthermore, studies 
suggest that OSA is a risk factor for severe COVID-19 illness (16-21). 
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This thesis investigates the connection between OSA and the incidence of 
cardiometabolic diseases and their risk factors, how genetic variation influences 
the risk for OSA and whether there is an increased risk for severe illness when 
contracting novel respiratory viruses among OSA patients. 
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2 REVIEW OF THE LITERATURE 
2.1 Sleep apnoea
Sleep apnoea is a common sleep-related breathing disorder causing reduced or 
absent breathing during sleep. Sleep apnoea is traditionally divided into three 
categories: OSA, CSA and mixed sleep apnoea, which is a combination of both 
OSA and CSA. OSA is clearly the most common of these forms (1, 2).  
CSA is defined by a lack of respiratory effort during cessations of airflow 
while asleep, in contrast to OSA where respiratory efforts are observed during 
the respiratory events. Several manifestations of CSA exist including idiopathic 
CSA, obesity hypoventilation syndrome, narcotic-induced CSA, and high altitude-
induced periodic breathing. The most important of the CSA manifestations is 
Cheyne-Stokes breathing, which is typically seen in medical disorders such as 
heart failure, cerebrovascular disorders, and renal failure (22). The prevalence of 
CSA strongly depends on its form and it is overall rare, affecting approximately 
1% of individuals (2). CSA is considered the primary diagnosis when ≥ 50% of 
apnoeas are scored as central in origin (22).
Mixed apnoea is a combination of OSA and CSA. It is typically characterized 
by absence of respiratory effort and airflow in the first section of the event, such 
as occurs in CSA, and respiratory effort without airflow in the last section, as it 
occurs in OSA (23). 
2.1.1 Overview of obstructive sleep apnoea
OSA is a disorder of repetitive pharyngeal collapse during sleep, where the 
pharyngeal airway lumen size is decreased by craniofacial structures or body 
fat (24). This could lead to an elevated probability of pharyngeal collapse in the 
majority of the OSA cases (25). Although this consequence is often seen in OSA, 
several other factors also contribute, including poor upper airway muscle function, 
low arousal threshold and low lung volume (26). Pharyngeal collapse can present 
as a complete collapse causing apnoea, or partial collapse causing hypopnoea. The 
airway is held open through the activity of upper airway dilator muscles which 
are highly active during wakefulness. During sleep the muscle activity is reduced, 
especially during deep sleep, and the airway collapses (27). Most often the collapse 
occurs at the level of oropharynx, with the extension to laryngopharynx (also 
referred as hypopharynx) is commonly observed (28), (Figure 1).  
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Figure 1. The upper respiratory system. In obstructive sleep apnoea, the pharyngeal collapse occurs 
most often at the level of oropharynx, with the extension to laryngopharynx commonly observed. 
This figure is adapted from Blausen.com staff (2014); "Medical gallery of Blausen Medical 2014" 
under the Creative Commons Attribution License.  
Pharyngeal collapses cause pauses in breathing which lead to acute adverse 
effects, including sleep fragmentation, fluctuations in blood pressure and heart rate, 
increased sympathetic activity, cortical arousal and oxyhaemoglobin desaturation. 
These adverse effects result in OSA causing cardiometabolic and neurocognitive 
consequences over time (4).
2.1.1.1 Prevalence
OSA prevalence in the general adult population is approximately 25% (1). An 
estimated 29.5% of Finnish individuals aged 30-69 have OSA (29). Concerningly, 
in the Wisconsin Sleep Cohort Study, 34% of men and 17% of women aged 30 to 
70 years had at least mild OSA with a 2-fold increased risk for men compared to 
women. The prevalence of OSA is tightly age dependent and it is increased among 
advanced age groups, with a prevalence of 43% in men and 28% in women among 
patients aged 50 to 70 years. OSA prevalence has increased approximately 30% 
between 1990 and 2010, along with population BMI, the most important risk 
factor for OSA (3). 
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2.1.1.2 Diagnosis
Diagnosing OSA is based on a comprehensive sleep evaluation where clinical signs 
and symptoms are measured. This consists of anamnestic information including 
a sleep-oriented history, physical examination, and findings from sleep testing. 
The diagnosis is always verified by sleep testing followed by the interpretation of 
a sleep specialist (30). 
2.1.1.2.1 Anamnesis and physical examination
The examination for OSA starts with an anamnesis including assessment of sleep 
history, which is typically obtained as a part of a routine health maintenance 
evaluation in a primary health care setting (30). Sleep history may be initially 
assessed by a questionnaire (e.g., Basic Nordic Sleep Questionnaire (31)) or the 
following questions can be used to screen whether a patient has a sleep disorder 
that requires clinical attention: 1) Does the patient suffer from difficulty falling 
asleep or daytime fatigue at least three days a week, 2) Does the sleep disorder 
impair the patient’s ability to function during the day.  If the answer is positive 
to at least one of the questions, it is appropriate to proceed with a more detailed 
examination (32). 
In the examination, the presence of obesity and OSA-predisposing craniofacial 
structures such as retrognathic jaws, tonsillar and adenoidal hypertrophy and 
increased neck circumference should be evaluated (30). Additionally, information 
concerning other diseases, medication, smoking status, alcohol consumption and 
shift work should be evaluated. OSA-related symptoms should also be assessed 
(see Table 1) (33-35). Positive findings on this OSA screen should lead to a more 
comprehensive evaluation of sleep history and physical examination (30). 
Table 1. Signs and symptoms suggestive of obstructive sleep apnoea (OSA)
Symptoms of OSA
Symptoms while awake Symptoms while asleep
Excessive daytime sleepiness Snoring
Morning headaches Respiratory interruptions 
Tendency to doze off Restless sleep
Memory impairment Night time perspiration
Difficulty concentrating Increase need to urinate during the night
Mood changes Heartburn
Impotence, impaired libido Dry mouth 
Coughing Drooling
Insomnia
The most common day and night-time symptoms associated with OSA according to previous studies 
(33-35). 
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When a patient is suspected of having OSA, a comprehensive sleep history 
should include an evaluation for snoring, witnessed apnoeas, gasping/choking 
episodes, total sleep amount, nocturia, morning headaches, sleep fragmentation/
sleep maintenance insomnia, decreased concentration and memory, and excessive 
sleepiness not explained by other factors (30). The Epworth Sleepiness Scale 
(ESS) is used to assess the severity of sleepiness. The ESS is an eight-question 
questionnaire which measures an individual’s general level of daytime sleepiness, 
or their average sleep propensity in daily life (36). Secondary conditions that may 
be caused by OSA, including hypertension, myocardial infarction, pulmonary 
heart disease, diabetes, stroke, decreased daytime alertness, depression and also 
medication and a history of motor vehicle accidents, should be screened (30). 
An increased risk of OSA can be recognised through a physical examination 
and therefore an inspection of respiratory, cardiovascular, and neurologic systems 
should be carried out (37). Features to be evaluated that may suggest the presence 
of OSA include a BMI ≥30 kg/m2, increased neck circumference (>43 cm in men, 
> 41cm in women), a score of 3 or 4 on the modified Mallampati scale (originally 
created to predict difficult tracheal intubation, but which can be used in general 
to estimate narrow airways (38, 39)) and certain characteristics of craniofacial 
structures such as the presence of retrognathia and/or opening growth direction 
of the lower jaw, macroglossia and nasal abnormalities (40, 41). 
Following anamnesis and physical examination, patients can be classified 
according to their risk for OSA. The high-risk category includes obese patients 
or those with cardiometabolic comorbidities such as treatment-resistant 
hypertension, type 2 diabetes (T2D), heart failure, atrial fibrillation, stroke, 
nocturnal dysrhythmias, pulmonary hypertension and professional drivers or 
pilots. High risk patients should be prioritised to have their diagnoses and disease 
severity assessed by out-of-centre sleep study (OCST) or polysomnography (PSG) 
testing (30).
2.1.1.2.2 Sleep testing
A diagnosis of OSA must always be established through in-laboratory or ambulatory 
PSG or OCST (30).
Overnight PSG in a laboratory is the gold standard for diagnosing OSA, with 
the primary outcome measure being the apnoea-hypopnoea-index (AHI). The 
definitions for apnoea, hypopnoea and the measurements mainly used to assess 
these are outlined in Table 2. PSG includes concurrent screening of both sleep 
and respiration. To follow the sleep–wake state, electroencephalogram, left and 
right electrooculogram, and chin electromyogram are documented. The recording 
of respiration includes airflow monitoring, respiratory effort measurement and 
oxygen saturation. Additional recommended parameters include body position 
and leg electromyography derivations (30).
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Table 2. Definitions for the main measurements concerning obstructive sleep apnoea
Measure Definition
Apnoea Apnoea is scored when there is a drop in the peak signal 
excursion by ≥ 90% of pre-event baseline for ≥ 10 seconds. 
Hypopnoea Hypopnoea is scored when the peak signal excursions 
drop by ≥ 30% of pre-event baseline for ≥ 10 seconds in 
association with either ≥ 3% arterial oxygen desaturation 
or an arousal.
AHI: Apnoea-hypopnoea-index The average number of apnoeas and hypopnoeas per hour 
of sleep.
REI: Respiratory event index The average number of apnoeas and hypopnoeas per hour 
of sleep, measured during out-of-centre sleep study. 
ODI3 or ODI4: Oxygen 
desaturation index
The oxygen desaturation index is the number of times per 
hour of sleep that the blood's oxygen level drop 3 or 4 
percent from the baseline.
The definitions are based the American Academy of Sleep Medicine (AASM) published rules for 
scoring respiratory events in the AASM Manual for the Scoring of Sleep and Associated Events (23).
As the diagnosis of OSA is defined by PSG, the protocol is time consuming 
and expensive. OCST has been evaluated to have 80% specificity when compared 
to PSG and thus it has been increasingly investigated as a diagnostic alternative 
to PSG (42). However, if the finding of OCST is mild or moderate, but the patient 
appears to have severe OSA by clinical assessment, the examination should be 
re-done with PSG or OCST or the patient should have a treatment trial with a self-
adjusting continuous positive airway pressure (CPAP) appliance (33). OCST may 
underestimate AHI and thus a fraction of OSA patients may remain undiagnosed 
when OCST is used (43). 
A diagnosis of OSA is confirmed if AHI on PSG or respiratory event index 
(REI) on OCST is ≥15 events per hour or ≥5 per hour in addition to either signs 
or symptoms for OSA (e.g., snoring, fatigue, associated sleepiness, insomnia, 
nocturnal respiratory disturbance, or observed apnoea) or associated medical or 
psychiatric disorder (i.e., hypertension, diabetes, coronary heart disease (CHD), 
heart failure, atrial fibrillation, stroke, cognitive dysfunction, or mood disorder). 
OSA severity is defined as mild for AHI or REI ≥5 and <15, moderate for AHI or 
REI ≥15 and ≤30, and severe for AHI or REI >30 per hour (44).
2.1.1.2.3 Distribution of care between health care sectors
Diagnosis and treatment of OSA involve cooperation between primary and 
secondary health care sectors. In primary care, OCST can be ordered when OSA 
is suspected. Patients with high-risk occupations, such as pilots and professional 
drivers, and patients with moderate or severe OSA should be referred to a secondary 
21
health care visit. Evaluation of CPAP treatment and OSA surgery takes place in 
the secondary health care sector (33). 
2.1.1.3 Risk factors
Several predisposing factors for OSA are known, including obesity and certain 
craniofacial structures. In addition, male sex has been established as one of the 
main risk factors for OSA, as males have a three- to five-fold OSA risk compared to 
females (10, 41, 45-57). The most relevant risk factors and associated comorbidities 
are presented below and are outlined in Figure 2. 
Figure 2. Predisposing factors for obstructive sleep apnoea (OSA) and its known comorbidities. Risk 
factors and comorbidities for OSA are gathered from previous studies concerning OSA (10, 41, 45-57).
2.1.1.3.1 Genetic factors
Genetic factors predisposing individuals to OSA are mainly unstudied, but 
important existing studies and findings are presented in the section: “7.2.2 Genetic 
studies concerning sleep apnoea”.  
2.1.1.3.2 Demographic factors
OSA has been considered mainly a male disease with male-female ratios (varying 
from 3:1 to 5:1) indicating that women with OSA are less likely to be diagnosed 
than men (58). Furthermore, OSA in women may be diagnosed later than in men 
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or may not be effectively treated (59, 60). Women have been shown to have higher 
impairment of quality of life and their healthcare disbursements have been higher 
compared to males with similar AHI values (61).
Increasing age is an established risk factor for OSA. The Wisconsin Sleep 
Cohort Study revealed in unadjusted estimates that 34% of men and 17% of women 
aged 30 to 70 years had at least mild OSA. and the corresponding percentages 
were 43% and 28% among patients aged 50 to 70 years (3). In addition, it is 
estimated that individuals aged 65 or older have a 2- to 3-fold OSA risk compared 
to individuals aged 30-64 years (62, 63).
2.1.1.3.3 Obesity
Overweight and obesity are defined as abnormal or excessive fat accumulation 
that presents a risk to health. WHO has created a classification to assess weight 
by BMI, defining underweight as <18.5 kg/m2, normal range as 18.5-24.9 kg/m2, 
overweight as 25.0-29.9 kg/m2 and obesity as ≥30 kg/m2 (64).
Obesity is the most important risk factor for OSA. Two out of three OSA 
patients are overweight. Strong epidemiological evidence suggests that excess 
weight is a causal factor for the development of OSA (24). A 10% weight gain is 
associated with a 6-fold increased risk for OSA in individuals who have not had 
OSA at baseline and an approximately 32% increase in AHI for those with OSA. 
Comparably, among patients who have lost weight a significant improvement in 
OSA severity has been seen; a 10% decrease in weight has been associated with 
a 26% decrease in AHI (65).  
2.1.1.3.4 Craniofacial structures
Craniofacial and upper-airway structures are important characteristics in the 
development of OSA (66). Influencing factors include skeletal or soft tissue 
variations and anomalies, which are often linked to convex facial profile, the 
presence of retrognathia and/or opening growth direction of the lower jaw, 
increased anterior lower facial height, high arched/narrowed hard palate, tonsillar 
and adenoidal hypertrophy, macroglossia, elongated/enlarged uvula, elongation 
of the soft palate, inferiorly positioned hyoid bone and narrowed nasal cavities. 
These features cause upper airway narrowing and thus predispose an individual to 
the development of OSA (40, 41). Among children, enlarged tonsils and adenoids 
might cause unfavourable growth rotations of the lower jaw and hence increase 
the risk for OSA (67). 
2.1.1.3.5 Hormonal changes
In women, sex hormone levels are largely changing during menarche, pregnancy 
and menopause. Sex hormones regulate respiration both directly and through 
central neuromodulatory serotonergic neurons, essentially involved in the neural 
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control of breathing (68, 69). Thus, it is likely that sex hormone variation has an 
effect on the risk of developing OSA. It was shown that postmenopausal women 
had a 3-fold increased risk in comparison to premenopausal women to have 
moderate or severe OSA, independent of other potential confounding factors. This 
association was attenuated when comparing postmenopausal hormonal therapy 
users with premenopausal women (46). In addition, hormone therapy users 50 
years or older compared with individuals who are not using hormonal therapy 
showed a significant 45% reduced risk for OSA (70). However, a randomized trial 
involving postmenopausal women revealed only a mild association with hormone 
therapy in reducing AHI (71). 
OSA is one of the most common comorbidities among acromegaly patients, 
affecting 20% to 80% of individuals (48). Hypersecretion of growth hormone and 
insulin-like growth hormone leads to upper airway narrowing by pharyngeal soft 
tissue swelling and macroglossia (72, 73). OSA is also considered a clinical marker 
of acromegaly when defining the diagnosis (74). Whether acromegaly is treated 
with medication or surgery, AHI is significantly reduced (75). 
2.1.1.3.6 Nasal congestion
Nasal congestion can be caused by anatomy, acute upper respiratory infection, or 
allergic rhinitis. All the above have been associated with snoring and OSA (45). 
OSA has been observed to worsen during the allergy season among patients who 
are suffering from seasonal allergic rhinitis. The risk for OSA has been shown to 
be increased 1.8-fold when comparing individuals with chronic nasal congestion 
to no nasal congestion (47).   
2.1.1.3.7 Alcohol consumption, smoking and drug usage
Alcohol consumption has been seen to increase the risk of OSA 1.25-fold when 
comparing alcohol-users and non-alcohol users (76). Alcohol ingestion increases 
upper airway collapsibility and induces apnoeic episodes (77). Smoking also has 
detrimental effects on OSA associated with airway inflammation, nasopharyngeal 
oedema and smoking-related diseases (49, 78).  
Medications and substances that relax muscles or suppress respiratory drive 
(e.g., benzodiazepines, and opioids) may also contribute to OSA risk and should 




There are at least three potential mechanisms for how OSA interacts with its 
associated cardiometabolic diseases, such as T2D, hypertension, CHD and stroke 
(Figure 3). First, OSA causes intermittent hypoxia which leads to increased 
oxidative stress. This oxidative stress further causes systemic inflammation and 
increases sympathetic activity. Second, intrathoracic pressure changes lead to 
excessive mechanical stress on the heart and large arteries. Third, arousal-induced 
reflexive sympathetic activation results in repetitive increases in blood pressure (5).
Figure 3. Potential mechanisms of the interactions between obstructive sleep apnoea and cardio-
metabolic diseases. 
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2.1.1.4.2 Cardiovascular risk factors
The prevalence of hypertension is linked with OSA severity ranging from 30 to 
80% prevalence from mild to severe OSA (50).  In addition, moderate to severe OSA 
is associated with a 3-fold increased risk for developing hypertension compared 
to individuals who do not have OSA (80). Each apnoeic event per hour increases 
the odds of hypertension by 1% (81). 
Patients with hypertension are also diagnosed with OSA in approximately 
40% of cases. OSA is even more common among patients with treatment resistant 
hypertension, as OSA is diagnosed in 83% of these patients (82).  Importantly, 
the treatment of OSA is associated with a significant reduction in both systolic 
and diastolic blood pressure (83, 84) and a positive correlation has been shown 
between number of hours of CPAP use (especially in patients with at least 4 hours 
of use per night) and the decrease in blood pressure levels (85).
The association between OSA and plasma lipid levels has been under 
investigation. The prevalence of hyperlipidaemia varies from 15.1% in subjects 
without OSA to 26.1% in patients with OSA (86). As OSA and hyperlipidaemia are 
both strongly linked with cardiovascular diseases, there is also evidence that OSA 
severity associates independently with cholesterol and triglyceride concentrations. 
High density lipoprotein (HDL) in particular has been shown to be significantly 
reduced as AHI increased (87). Furthermore, CPAP treatment may improve 
dyslipidaemia by decreasing total cholesterol and low density lipoprotein and 
increasing HDL (88).
Current smoking is an established risk factor for cardiovascular disease, 
and the risk remains significantly elevated for at least 5 to 10 years after cessation 
relative to never smokers (89). Smoking has not only been shown to associate with 
cardiovascular disease, but also increases OSA severity (78). 
2.1.1.4.3 Cardiovascular diseases
Based on epidemiological studies, OSA associates with many different forms of 
cardiovascular diseases such as CHD, atrial fibrillation, and stroke (6). OSA is highly 
prevalent as it is estimated to affect 40% to 60% of patients with cardiovascular 
disease (7). 
In a prospective longitudinal epidemiological study, the Sleep Heart Health 
Study, OSA was found to be a significant predictor of CHD, increasing the risk 
by 10% per 10-unit increase in AHI after adjustment for multiple risk factors. 
Interestingly, this risk was observed in men aged 70 years or younger, but not 
in men over 70 years or in women (90). In addition to AHI, hypopneas with 
an oxyhaemoglobin desaturation of 4% or more associated independently with 
cardiovascular disease (91). 
The association of OSA severity to cardiovascular outcomes has also 
been investigated. A meta-analysis consisting of 16 cohort studies and 24,208 
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individuals suggested that severe OSA is associated with increased CHD risk by 
63%, moderate OSA by 38%, but no significant association was seen between 
mild OSA and CHD (92).  
OSA is highly prevalent among stroke patients and the reported frequencies 
vary from 30% to 80% (93). Based on the aforementioned meta-analysis, severe 
OSA was associated with a 2.15-fold increased risk of stroke, but no association 
was observed between moderate or mild OSA and stroke (92). This finding is in 
line with a landmark study where an independent association between severe 
OSA and stroke was found (94).  
2.1.1.4.4 Type 2 diabetes and its complications 
Many comorbidities of OSA overlap with the comorbidities of T2D including obesity 
and hypertension. It has been suggested that OSA has a role in the progression 
of metabolic syndrome through the development of insulin resistance (5). The 
prevalence of OSA among T2D individuals is estimated to be between 58 to 86% 
(55, 95). Similarly, the unadjusted prevalence of T2D increases with OSA severity, 
with a 7% prevalence among OSA-free individuals and 29% among patients with 
severe OSA. Furthermore, after adjusting for obesity and other confounding 
factors, severe OSA was associated with an increased risk for T2D by 1.87-fold, 
moderate OSA 1.73-fold and mild OSA 1.33-fold (96).  
OSA is also associated with T2D complications, such as kidney disease, 
indirectly through its adverse effects of hypertension, oxidative stress, and 
hypoxemia-related consequences (97). However, this association can be observed in 
both directions i.e., OSA may contribute to impaired renal function and impaired 
renal function may cause OSA. Therefore, OSA may also increase the risk for 
kidney dysfunction especially in the population of T2D individuals (98). 
2.1.1.5 Other comorbidities
In addition, numerous other comorbidities have been reported to associate with 
OSA including depression, hypothyroidism, asthma and inflammatory rheumatic 
diseases (IRD) (99-103).  
The prevalence of depression has been noted to be higher among OSA patients 
compared to OSA-free individuals and is related to OSA severity. The estimates 
of depression rates among OSA individuals vary from 17% to 41%. However, the 
connection between these two diseases is complex, as both depression and OSA 
share a number of similar symptoms such as fatigue and sleep problems (100). 
Additionally, hypothyroidism and OSA have overlapping symptoms. 
Hypothyroidism alone does not usually cause OSA, but if other risk factors, such as 
obesity or male gender, are present these may create a risk for OSA (53). In addition, 
the contributing factors for OSA include low respiratory drive, upper airway 
narrowing by myxedema or obesity (53, 104). Newly diagnosed hypothyroidism 
27
among OSA patients is not significant, but subclinical hypothyroidism is more 
prevalent in the OSA population (99). 
In addition to OSA, chronic obstructive pulmonary disease (COPD) is a 
common respiratory disease affecting 14% of men and 4% of women (105). OSA 
prevalence varies among COPD patients from 10% up to 65.5% (57, 106). Patients 
with COPD and OSA are at an increased risk of death and exacerbations of COPD 
if OSA remains untreated (107, 108). Concurrence of these diseases may potentially 
explain the high cardiovascular outcomes and mortality among these patients 
(105). 
Asthma patients have clearly more symptoms associated with OSA, such 
as snoring and shortness of breath, compared to OSA patients without asthma 
(109). In addition, the risk of having OSA is over 2-fold increased among asthma 
patients than asthma-free patients (101). It has also been found that treatment of 
OSA improves asthma symptoms significantly even among patients with asthma 
imbalance, and therefore unrecognized OSA may be a reason for persistent asthma 
symptoms (56, 110).
There is evidence that patients with IRD may be at increased risk for sleep 
disorders, particularly OSA (102). OSA might manifest as a comorbidity of these 
diseases by IRD affecting the temporomandibular joint. If the joint is affected, it 
may cause backward rotation of the lower jaw leading to narrowing of the upper 
airway (103).
2.1.1.6  Mortality
Severe OSA has been identified as an independent risk factor for mortality (51, 
52). According to a meta-analysis of 17 studies concerning all-cause mortality with 
681,072 deaths documented, severe OSA was associated with a 2.13-fold increased 
risk for all-cause mortality and, similarly, a subset of the data revealed a 2.73-fold 
risk for cardiovascular mortality (111). Importantly, long-term CPAP use showed 
reduced mortality rates among OSA patients (112).
2.1.1.7 Treatment and outcomes 
Treatment of OSA requires long-term and multidisciplinary treatment. The 
treatment methods include conservative, medical, and surgical options.
2.1.1.7.1 Conservative treatment
Conservative treatment options are the most important part of care for OSA 
patients. These treatments include weight reduction, as it has been seen to reduce 
AHI in obese individuals. Weight loss may also benefit management of other 
existing comorbidities such as hypertension and high cholesterol (113). Exercising 
has been seen to lower AHI in addition to helping with weight control even without 
weight reduction (114). Positional therapy, avoiding a supine position during sleep, 
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can also reduce AHI significantly among patients who are suffering supine-
position-related OSA (115). OSA patients should be advised on the importance of 
regular sleeping habits as sleep deprivation worsens OSA (116). These factors should 
be taken into consideration also when a patient has irregular working shifts (33). 
Medications and substances that relax muscles or suppress respiratory drive 
(e.g., alcohol, benzodiazepines, and opioids) may also exacerbate OSA and should 
be minimized or avoided (79). 
2.1.1.7.2 Continuous positive airway pressure 
CPAP is the gold standard for OSA treatment in moderate or severe cases (117). 
CPAP directs a generally constant pressure to the upper airway, hence preventing 
pharyngeal collapse. CPAP has been shown to significantly decrease AHI (118). 
Patients with severe OSA benefit most from CPAP treatment. CPAP therapy 
significantly reduces both systolic and diastolic blood pressure, but with low 
effect size; 2.6±0.6 mmHg and 2.0±0.4 mmHg, respectively (83). Among other 
positive effects of CPAP treatment, it may also improve sleep-related symptoms 
and quality of life (119). 
CPAP therapy’s effects on cardiovascular outcomes and mortality rates range 
from significant prevention to non-significant findings (111, 120). However, a recent 
prospective cohort study showed that patients who had used a CPAP device for 
over 5 years were more than 5 times more likely to be alive at the end of the follow 
up (mean follow up 14 years) than non-CPAP users. In addition, long-term CPAP 
users were 1.74-times more likely to be alive than patients who had used a CPAP 
≤ 5 years (112).
Despite several advantages of CPAP use, it may be problematic for some 
patients (121). Difficulty with a CPAP device may arise from a combination of mask 
discomfort, claustrophobia, pressure intolerance or lifestyle and social factors (118).
2.1.1.7.3 Mandibular advancement device 
A mandibular advancement device (MAD) increases the upper airway volume 
during sleep by enlarging the pharyngeal airway and by preventing upper 
airway collapsibility. MAD covers the upper and lower teeth (the upper jaw 
may be toothless) and holds the mandible in a forward position during sleep 
(122). Mandibular protrusion advances the tongue position and subsequently 
increases oropharyngeal volume (123). 
First line treatment for moderate and severe OSA is CPAP, but MADs may 
be used in patients who cannot tolerate CPAP and have a BMI under 30 kg/m2 
(30).  In addition, MAD can be prescribed without a CPAP trial if a patient refuses 
CPAP therapy and AHI is under 30 events per hour and BMI under 30 kg/m2 (33). 
In patients with mild to moderate OSA, a reduction of AHI of over 50% was 
observed among 42.8% of MAD users (124, 125). In addition to the positive effects 
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to AHI, MAD treatment also reduces daytime sleepiness and improves quality 
of life (126). BMI has a significant impact on the success of MAD treatment and 
treatment outcomes are not as good among overweight individuals as in patients 
with normal weight (127). Leaner patients or patients with supine-dependent OSA 
have been reported to experience particular success with the device (126). There 
is evidence that individuals having asthma as a comorbidity of OSA would benefit 
from MAD treatment, as it has been shown to reduce asthma symptoms even in 
patients with imbalanced asthma (110). 
2.1.1.7.4 Otolaryngologic surgeries
Among children and adolescents, hypertrophy of tonsillar and adenoid tissues 
can cause obstruction of the nasopharyngeal and oropharyngeal areas. Therefore, 
adenotonsillectomy or tonsillectomy can be considered first-line treatments for 
paediatric OSA (128, 129). In addition, it has been found that tonsil surgery has 
a positive effect on the growth direction of the mandible (67). Among adults, 
tonsillectomy may be a successful treatment for OSA, especially for patients with 
large tonsils and mild or moderate OSA (130).
Nasal obstruction can increase snoring and OSA. Intranasal pathology may 
increase resistance in the upper airway, which might lead to a subsequent collapse 
and cause hypopnoeas. Surgical techniques include septoplasty and removal of 
the concha bullosa, which may decrease airway resistance and can cure OSA in 
some and facilitate CPAP comfort for others (131).
The goal of using radiofrequency ablation (RFA) for treatment of OSA is 
tissue volumetric reduction (132). In one study, short term follow-up (under one 
year) showed a significant 31% reduction in the respiratory disturbance index 
(RDI) and, similarly, in ESS of 31%. After long-term follow-up (over 2 years) RDI 
showed a 45% reduction and ESS a 32% reduction (133). Tongue base RFA can 
be done alone or simultaneously with other upper airway surgical procedures. 
Clinically, the most common adjuvant procedure addresses palatal obstruction: 
uvulopalatopharyngoplasty (UPPP) (132).
The procedure of UPPP is designed to enlarge and stabilize the retro-palatal 
airway (134), but its efficacy in improving AHI is low, with around 41% reported 
success rate, although many patients improved subjectively (135). This seems to 
support the hypothesis that multiple levels of obstruction exist and explains why 
UPPP alone frequently results in a lack of symptom improvement.
Tongue-based surgeries are an option to treat lower pharyngeal obstruction 
with genioglossus advancement including hyoid suspension (136). The procedure 
is often an adjunctive intervention with UPPP, as success rates have been found to 
be higher in multiple-level surgeries than in tongue-based surgeries alone (76%, 
70%, respectively) (137, 138). 
30
As the obstruction of the upper airway may occur in multiple sites, patients 
may benefit from multilevel surgeries when treating OSA. These may include 
nasal, palatal, and tongue surgeries, and can be performed simultaneously or in 
a phased sequence (139, 140).
2.1.1.7.5 Orthognathic surgery
Maxillo-mandibular advancement is a skeletal surgery which relocates maxilla and 
mandible anteriorly by LeFort I and bilateral sagittal split osteotomy. In addition 
to bony structures, the procedure advances anterior pharyngeal tissues such as the 
base of tongue, the soft palate and suprahyoid musculature, creating more volume 
in the velo-oro-hypopharyngeal area (141). Suggested indications for this procedure 
include hypopharyngeal narrowing, velo-oro-hypopharyngeal narrowing, and 
possible retrognathia of the mandible or both maxilla and mandible, but the 
procedure is also adequate even in absence of craniofacial skeletal deformities (142). 
The recommended minimum advancement of the mandible is 10 mm (143). 
The treatment is highly effective as, according to a meta-analysis, it reduces AHI 
by 76%, with a mean preoperative AHI of 53.4 and postoperative AHI of only 
12.9. Additionally, for every 1 mm of mandibular advancement, the post-operative 
AHI was lowered by an average of 1.45 events/hour, and each 1mm advancement 
also induced a 0.5mm gain in pharyngeal airway space, which is defined as the 
minimum distance between the base of the tongue and the posterior pharyngeal 
wall (144). However, mandibular setback, which can be used to correct mandibular 
prognathism causing a relative narrowing of the upper airway, has not been seen 
to trigger OSA (145). 
Jaw advancements may cause prognathism for patients with a normal 
preoperative maxillomandibular position and therefore aesthetic planning should 
be included when considering this surgical procedure. However, postoperative 
appearance is regarded as unsatisfactory by only 5.2% of patients who have 
undergone maxillomandibular advancement surgery (146, 147).
2.1.1.7.6 Bariatric surgery
Bariatric surgery is an effective treatment approach for obesity, with resultant 
improvement in obesity-related comorbidities such as OSA. OSA has been found to 
be improved or cured in 78% patients who undergo bariatric surgery, but moderate 
or severe OSA persist in 20% of patients after the operation. However, an important 
finding regarding OSA treatment is that AHI was found to be reduced significantly 
from 27.8 events per hour to 9.9 events per hour on average (148).  
2.1.1.7.7 Hypoglossal nerve stimulation
A hypoglossal nerve stimulator protrudes the tongue by hypoglossal nerve 
stimulation, opening the pharyngeal airway. The device is implanted in the chest, 
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and it is connected to a wire that attaches to a small cuff on the hypoglossal nerve 
(149). The treatment can be considered for individuals over age 18 with AHI 15-65 
events per hour, BMI under 32 and for patients who have been unable to tolerate 
CPAP or other treatment options (150). This method reduced AHI efficiently, 
showing a 68% improvement in a 3-year follow-up (151). However, it has also 
been reported that this method did not reduce AHI or ≥4% oxygen desaturation 
index (ODI) values significantly and weight gain was observed in patients during 
the treatment. In addition, the costs of the treatment may be high (152). 
2.1.1.8 COVID-19 associations with obstructive sleep apnoea
OSA leads to a significant cost to individuals and society, especially because it 
is associated with higher risks of cardiometabolic diseases as well as increased 
mortality rates. During the year 2020 another serious respiratory-related disease 
- COVID-19 - emerged, increasing disease burden on both at the individual and 
health care levels. On this basis, concerns have been raised about the health burden 
of OSA and COVID-19 together, as both have effects on respiration, particularly 
through decreased oxygen saturation levels. 
Coronaviruses are a large group of viruses that can infect both humans 
and animals. They cause mostly mild respiratory infections, but also serious life-
threatening diseases such as severe acute respiratory syndrome and Middle East 
respiratory syndrome, and currently COVID-19. Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) is a new virus in humans causing the respiratory 
illness COVID-19, with variation in the severity of the symptoms, spreading from 
person-to-person primarily through respiratory droplets and aerosol particles (14).
The first reported COVID-19 cases occurred in Wuhan, Hubei province, 
China, in late December 2019. The virus spread rapidly, and on March 11th, 2020 
WHO made the assessment that COVID-19 was characterized as a pandemic. Most 
people with the virus recover well and spontaneously, but data from several 
countries have shown that 14% to 19% of infected individuals require hospital 
treatment (14). The reported hospitalisation rates have been highly age-dependent. 
Of all hospital admissions due to COVID-19, 0.4% have been aged 0–4 years, 
another 0.4% aged 5–17 years, 24.7% aged 18–49 years, 31.1% aged 50–64 years, 
and 43.4% aged ≥65 (153). In addition, the risk for in-hospital deaths were highly 
increased among the older age groups, showing an elevation of risk to 3.11-
fold for 50-64 year olds, 5.77-fold for 65-74 year olds, 7.67-fold for 75-84 year 
olds and 10.98-fold for over 85 year olds compared to individuals aged 18-39 
years (after adjusting for confounding factors, such as sex, obesity, diabetes and 
immunosuppression) (154).  
Known risk factors for severe COVID-19 disease include male sex, older 
age, obesity, diabetes, cardiovascular disease, and decreased lung function (15). 
Therefore, severe COVID-19 and OSA share several common risk factors and 
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comorbidities. In addition, previous studies have suggested OSA is a risk factor 
for the severe form of COVID-19 (17-21). This risk might have a considerable effect 
on healthcare systems as OSA is a very common disease and a large fraction of 
the cases are undiagnosed. One study even suggested that OSA might increase 
the risk of contracting COVID-19 (18).
Several potential mechanisms for how OSA associates with COVID-19 have 
been suggested. First, OSA causes continuous low-grade inflammation (5), which 
may be of particular importance in obese patients as it may potentially contribute 
to the intensification of the cytokine storm that occurs in COVID-19 pneumonia 
(155). Second, OSA may predispose individuals to pneumonia due to upper airway 
microaspiration, which has been suggested as the main mechanism leading to viral 
pneumonia (156). Third, OSA may worsen the core symptoms of severe COVID-19, 
especially during the night, when decreased oxygen saturation levels occur in 
OSA (5).
2.2 Genetics of common complex diseases
A complex disease is defined as a trait affected by multiple genes and environmental 
factors. There are many diseases which fulfil this criteria, such as Alzheimer's 
disease, Parkinson's disease, kidney diseases and autoimmune diseases (157). 
OSA is also a common complex disease; it is a mixture of genetics, lifestyle, and 
environmental factors which include socioeconomic status and diet. Genetically 
several genes predispose one to OSA (known as a polygenic disease), in contrast to 
monogenic diseases, which are caused by a single gene or a single variant. Polygenic 
diseases are caused by the common contribution of several independently-acting 
or interacting polymorphic genes. However, the contribution of each gene may 
be small or even unnoticeable. The presence of certain combinations of alleles 
can influence the occurrence of the disease and therapeutic efficacy of certain 
pharmaceutical drugs (158). 
2.2.1 Human genetic variation
The human genome includes 3.2 billion nucleotides which are divided into 
chromosomes. There are 22 autosomal chromosomes and two sex chromosomes 
(the X chromosome and the Y chromosome). Normally, humans have two copies of 
each autosome and individuals with one copy of X and one of Y are male whereas 
individuals who have two copies of X are female. 
Genetic information is carried in a sequence of nucleotides of deoxyribo-
nucleic acid (DNA). Each molecule of DNA is a double helix formed from two 
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complementary strands of nucleotides held together by hydrogen bonds between 
cytosine (C) – guanine (G) and adenine (A) – thymine (T), Figure 4. 
Figure 4. Structure of deoxyribonucleic acid (DNA). Chromosomes have proteins called histones that 
bind to DNA. DNA has two strands that twist into a helix. DNA is made up of four building blocks 
called nucleotides: adenine (A), thymine (T), guanine (G), and cytosine (C). The nucleotides attach 
to each other (A with T, and G with C) to form chemical bonds called base pairs, which connect the 
two DNA strands. The figure is adapted from pixabay.com under the Pixabay License.  
Single nucleotide polymorphisms (SNPs) are points in the genome sequence 
where a sufficiently large fraction of the human population (e.g., >1%) has one 
nucleotide (e.g. an allele) while another large fraction has another. Therefore, an 
allele which is common in one geographical or ethnic group may be much rarer 
in another. At a location in the genome where there are two alleles, the SNP with 
lower frequency can be called the minor allele in a certain population, and its 
frequency is called the minor allele frequency. 
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Mapped sites in the human genome that are polymorphic, meaning that 
there is a reasonable probability that the genomes of two individuals will differ 
at this site, are extremely useful for genetic analyses. These analyses, including 
GWASes, compare altered allele frequencies between cases and controls or people 
with different phenotypes for a particular trait, for example for blood pressure. 
A correlation structure exists throughout the human genome across genetic 
variation of different loci.  This correlation structure allows us to use the genotype 
information at one locus to supply information about the genotype at another locus. 
This correlation between variation at different loci is called linkage disequilibrium 
(LD) (159). LD between two loci diminishes in proportion to the recombination 
rate and time when measured in generation numbers. Positive LD presents if two 
alleles are seen together on the same haplotype more often than expected, and 
negative LD presents if alleles are seen together on the same haplotype less often 
than expected (160). LD has implications in many methods of genetic research 
including population genetics and association studies (159). 
2.2.1.1 Genetic characteristics of Finns
The Finnish population offers a unique environment for genetic research. This is 
mainly due to the small size of the indigenous population, the country's settlement 
history, the numerous so-called bottlenecks and centuries of geographical and 
cultural isolation with low amounts of immigration (161, 162). A bottleneck-effect 
occurs when a population’s size is reduced, for example by a violent conflict. When 
the population expands after the event it is more genetically similar than before. 
Another special feature is due to settlement, showing that the genetic difference 
among Finns is relatively high between Eastern and Western parts of Finland. 
This genetic difference between Eastern and Western Finnish populations is even 
higher than that between German and British populations. Based on this unique 
history of the Finnish population and the enrichment of certain variants, a smaller 
number of Finns is sufficient to achieve adequate statistical power compared to a 
population where the disease would be very rare (163).
Importantly, studies have revealed a group of 36 monogenic diseases, called 
the Finnish disease heritage. These diseases are more frequent in Finland than 
in any other population, but on the other hand some diseases which are common 
in other populations do not exist among Finns (164, 165). These studies have not 
only highlighted the molecular mechanisms of Finnish diseases, but also showed 
information on the biological processes and metabolic pathways which are required 
for normal development and function of cells and tissues (165). In addition to 
the Finnish disease heritage, genetic variants enriched in the Finnish population 
have also been associated with many other diseases. For example, these variants 
have been linked with cholesterol levels and differences in levels of amino acids 
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in the blood, which are linked to several health problems including liver or kidney 
dysfunction in addition to changes in height and body weight (163, 166).
2.2.2 Genetic studies concerning obstructive sleep apnoea
Genetic studies provide a tool to identify independent genetic risk factors that 
modulate disease risk, and to examine causal pathways between comorbid traits. 
Although the genetics of OSA is largely unstudied, reports have revealed 
that family members have a 2–4-fold greater risk of having OSA if there are OSA 
patients in the family. Although this can be caused partly by non-genetic factors, it is 
estimated that 40% of the variation in AHI is genetically regulated and can thus be 
explained by familial factors giving evidence of genetic predisposition to OSA (10). 
Twin and family studies have suggested that obesity, ventilatory responsiveness to 
hypoxemia and hypercapnia and craniofacial structures are strongly under genetic 
control as 30-70% of phenotypic variance has been explained by heritable factors 
(167-169). Presumably, genetic factors that contribute to the risk factors for OSA, 
such as craniofacial structures, body fat distribution and neural control, also have 
an effect on OSA predisposition (10). In addition, a study concerning over 4000 
Finnish twins found that the concordance for snoring, the most common symptom 
of OSA, was greater between monozygotic twins than between dizygotic twins, 
further suggesting a role for inheritance (170).
2.2.2.1 Candidate gene association studies 
Most genetic studies of OSA so far have been candidate gene association studies. 
The analyses in these studies depend on the hypothesis about the role of a selected 
gene on a certain phenotype. This single-gene method offers the advantage that 
predetermined genes can be prioritised and investigated first (171). Unfortunately, 
this method has given disappointing results, because there have been challenges 
replicating the findings and several studies have been underpowered (172). The 
limitations of the candidate gene approach are that inappropriate genes have been 
chosen for study and selection of genes relies on previous knowledge about disease 
mechanisms, which may prevent the finding of novel genetic variants in previously 
unknown pathways. Also, causative genes may be located either in the upstream 
or downstream signalling pathways of the selected genes (171). 
In the case of OSA, one difficulty with the candidate gene strategy lies in 
selecting genes associated directly to OSA and not establishing genetic links related 
to comorbidities. However, studies have validated a few genetic associations with 
OSA through candidate gene methods. Certain associated and replicated SNPs 
have been found, including a meta-analysis proving an association between OSA 
and rs1800629 in the Tumor necrosis factor alpha gene (173). A multiple-cohort 
candidate gene study including individuals from both European and African-
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American ancestry revealed two replicable SNPs associated with OSA: rs1409986 
in the Prostaglandin E receptor 3 gene and rs7030789 in the Lysophosphatidic 
acid receptor 1 gene (174). In addition, the Apolipoprotein E ε4 locus has been 
investigated by several studies, but a meta-analysis concluded that the evidence 
is not strong enough to suggest causal association between the Apolipoprotein E 
ε4 locus and OSA (175). It has been observed that several previously identified 
genetic associations with OSA may be false positives (176). 
2.2.2.2 Genome-wide linkage studies
The aim of genome-wide linkage studies is to use genotyped familial data to identify 
regions of the genome which are linked with the disease or a disease-associated 
phenotype without actually knowing the mutation in advance (177, 178). One 
genome-wide linkage analysis and follow-up association identified a connection 
between a marker of OSA severity and a polymorphism in the Angiopoietin-2 
gene (179). 
2.2.2.3 A short introduction to genome-wide association studies
A GWAS is an approach to study associations between genetic variants and 
diseases and/or traits in samples from populations. The primary goal is a better 
understanding of the biology of diseases, under the assumption that this will lead 
to better treatments or prevention. GWAS is facilitated by finding genetic regions 
with markers showing imbalance in their allele frequencies between disease cases 
and controls. These genetic regions are then further studied, or finemapped, to 
localize the likely candidate genes modifying the disease risk. 
Knowledge of common genetic variation of the human genome is provided 
by two major research initiatives: The International HapMap Project and 
The 1000 Genomes project. The International HapMap Project has described 
the patterns of common SNPs within human DNA sequences, documenting 
recombination hotspots, a block-like structure of linkage disequilibrium and low 
haplotype diversity that leads to substantial correlations of SNPs with many of 
their neighbours (180). The 1000 Genomes project has created the largest public 
catalogue of human genetic variation and genotype data with the goal of finding 
most genetic variants with frequencies of at least 1% in the populations studied 
(181).
Haplotype block structure suggests that the recombination of chromosomes 
occurs only at a relatively small number of sites on the genome. These sites are 
called recombination hotspots (180). Phasing, which is a process of analysing 
known genotypes to infer haplotypes, can be performed accurately by collecting 
large numbers of genotyped samples and utilizing a probability model for 
estimating which are the most probable haplotypes in the study population. 
The accuracy is further improved by high quality reference data. Tag-SNPs are 
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representative SNPs in a region of the genome with high LD that represent 
a haploblock. Therefore, it is enough to genotype any tag-SNP of a causal SNP 
within a haploblock (182). 
GWASes have been based on data from SNP arrays designed to tag common 
variants in the genome combined with stochastic imputation of non-genotyped 
markers using a reference panel from a set of whole-genome sequenced individuals. 
Modern genotyping arrays can genotype up to 106 markers simultaneously, while 
imputation may further increase the number of SNPs up to several millions. 
Imputation is a process of predicting genotypes that are not directly genotyped 
in a sample of individuals by using known haplotypes in a population, for instance 
from the HapMap or the 1000 Genomes Project (182). Importantly, it is one of the 
main uses of haplotype structure in GWAS. 
Genome-wide association tests are used to identify regions of the genome 
associated with the phenotype of interest. For each SNP it is tested if the allele 
frequency significantly varies between the case and the control groups (183). 
Identification of trait-associated SNPs may subsequently reveal new insights into 
the biological mechanisms underlying these phenotypes. To date, genome-wide 
association studies have identified > 4,000 associations with diseases and traits 
(184).
2.2.2.3.1  Examples of genome-wide association studies
GWAS is nowadays a popular method when studying the genetics of common 
complex diseases. Below are represented brief examples of recent studies closely 
related to OSA comorbidities.
A meta-analysis has combined GWASes of T2D including 62,892 T2D cases 
and 596,424 controls of European ancestry with 16 million genetic variants. The 
study revealed 139 common and four rare variants, with 39 novel loci associated 
to T2D. These findings provided insights into the T2D aetiology, estimating the 
genetic structure of the trait and suggesting T2D is a polygenic disease. Both rare 
and common variants contribute to the genetic variation and it is indicated that 
rarer variants have larger effects on T2D risk (185).
It is established that obesity is heritable, and that it also predisposes one 
to many other diseases. To clarify the genetics of obesity utilizing BMI values, 
a GWAS was performed including 339,224 individuals. The study revealed 97 
BMI-associated loci with 56 novel findings.  Five of the loci showed evidence of 
several independent association signals, and many loci have significant effects 
on other metabolic phenotypes. The 97 loci explained 2.7% of BMI variation, and 
genome-wide estimates suggest that common variation accounts for over 20% 
of BMI variation. In addition, the role of the central nervous system in obesity 
susceptibility was suggested, implicating new genes and pathways including those 
38
related to synaptic function, glutamate signalling, insulin secretion/action, energy 
metabolism, lipid biology and adipogenesis (9).
2.2.2.3.2   Genome-wide association studies concerning sleep apnoea
GWASes regarding OSA have previously identified associations with OSA 
severity, measured with AHI or respiratory event duration. These findings show 
an association to inflammatory, hypoxia signalling, and sleep pathways among 
Hispanic/Latino Americans, an association with AHI during non–rapid eye 
movement sleep in men, but not in women and identified genetic loci associated 
with variation in AHI over time (11-13). These findings are outlined in Table 3. 
Although these studies have provided the beginning of the OSA GWAS era, the 
results have not been replicable, with the exception of the finding at rs12936587, 
which was replicated in a small, independent physiological research study including 
67 individuals (P=0.047) (13).   
Table 3. Main findings of the previous genome-wide association studies (GWASes) for obstructive 
sleep apnoea-related traits
1st author Trait Sample size GWAS finding P


















The main results of previous GWASes for OSA-related traits (11-13). AHI=apnoea-hypopnoea 
index, NREM=non-rapid eye movement sleep. The table is adapted from the manuscript Strausz 
et al. (2020) Genetic analysis of obstructive sleep apnoea discovers a strong association with 
cardiometabolic health.
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3 AIMS OF THE STUDIES
This thesis concentrates on studying the role of OSA among Finns in cardiometabolic 
comorbidities, how genetic variation influences the risk for OSA, and whether 
there is an increased risk for severe disease when contracting novel respiratory 
viruses among OSA patients. The studies use epidemiological and longitudinal 
ascertainment, and also utilize modern genetic methods. The aims of the studies 
are the following:
I. To evaluate in a longitudinal prospective setting a) whether OSA modifies 
the risk of CHD and T2D independent of known risk factors such as BMI, 
blood pressure and lipids, b) the role of OSA in the development of diabetic 
complications including diabetic kidney disease (DKD) and c) whether OSA 
has similar effects in women and men.
II. To identify novel genetic loci associated with OSA risk and to test if OSA 
and its comorbidities, such as hypertension, T2D, CHD, stroke, depression, 
hypertension, asthma, and IRD, share a common genetic background. 
III. To study whether OSA associates with the risk for severe COVID-19 
disease independent of other potential risk factors including age, sex, BMI, 
hypertension, diabetes (including type 1 diabetes and T2D), CHD, asthma, 
and COPD, and also whether the risk for contracting COVID-19 is elevated 
among OSA patients. 
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4 MATERIALS AND METHODS 
4.1 Healthcare system in Finland
The Finnish healthcare system is based on public healthcare services to which 
everyone residing in the country is entitled. According to the Constitution of 
Finland, the public authorities shall guarantee for every person adequate social, 
health and medical services (186). 
Municipalities are responsible for organising and financing health care. Health 
services are divided into primary health care and secondary medical care. Primary 
health care services are provided at municipal health centres. Municipalities form 
hospital districts which are responsible for providing secondary health care in 
hospitals in their area. In addition, joint municipal authorities belong to five 
catchment areas for highly secondary health care, which are formed around the 
University Hospitals of Helsinki, Turku, Tampere, Oulu and Kuopio and at which 
the most demanding treatment is provided. Private health services complement 
municipal services and private operators provide both primary health care and 
secondary health care services (186).
Data is systematically collected from all these health care providers into 
nationwide registries maintained by governmental organizations such as the Social 
Insurance Institution of Finland, Statistics Finland and The Finnish Institute for 
Health and Welfare (THL) (187). Therefore, the Finnish healthcare system enables 
long-term monitoring of inhabitants independent of individual socioeconomic 
background and allows for follow-up of individuals for up to their whole lifespan, 
or for example during their growth period (188). This results in the ability to share 
information among healthcare professionals and higher quality of care, but is also 
highly useful for research purposes.
4.2 Study population 
In all studies in this thesis a diagnosis of OSA is based on the International 
Classification of Diseases (ICD)-codes (ICD-10: G47.3, ICD-9: 3472A), which 
were obtained from the Finnish National Hospital Discharge Registry and the 
Causes of Death Registry. This diagnosis is based on subjective symptoms, clinical 
examination and sleep studies, applying the criteria of AHI/REI ≥ 5 per hour with 
associated signs/symptoms or medical/psychiatric disorder, or AHI/REI ≥ 15 per 
hour even in the absence of associated symptoms or disorders. 
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By combining ICD-codes from different registries, we generated the disease 
endpoints outlined in Table 4, which describes how endpoints were constructed 
for each phenotype.
Table 4. International Classification of Diseases (ICD)-codes for obstructive sleep apnoea (OSA) 
and comorbidities
Phenotype endpoint ICD-10 ICD-9 ICD-8
OSA G47.3 3472A





400, 401, 402, 403, 
404
T2D** E11 250A
CHD I20.0, I21, I22 410, 4110 410, 411,0
DKD N18, N19, E10.2, E11.2 585, 2503A, 2503B 582,00, 250,04
Stroke I61, I63, I64 431, 4330A, 4331A, 
4339A, 4340A, 
4341A, 4349A, 436
431, 433, 434, 436
Depression F32, F33 2961, 2968 790,20, 298,0
Hypothyroidism E00, E01, E02, 
E03.0-E03.5, E03.8, 
E03.9
243, 2443, 2448, 
2449, 2448A, 2448B
243, 244
Asthma J45, J46 493 493
IRD M05, J99.0, M06.0, 
M30-M35, M45, 
M08.0, L40.5
7140A, 7140B, 7141, 
7100, 7431, 7101, 
7340, 7200, 7143A, 
6960A
712,10, 712,4, 712,0, 
696,00
Snoring R06.5
Phenotype endpoints were generated by combining ICD-codes from different registries. The Finnish 
national version for each ICD-code was used. These ICD-code criteria are all regular expressions 
for a hierarchical search. Hypertension* also includes Social Insurance Institution of Finland 
reimbursement code 205. T2D** includes also medication purchases for Anatomical Therapeutic 
Chemical code A10B, Blood glucose lowering drugs, excluding insulins. At least three separate 
purchases were required to ensure the correct diagnosis if diabetic medication was the only 
evidence. T2D=type 2 diabetes, CHD=coronary heart disease, DKD=diabetic kidney disease, IRD= 
inflammatory rheumatic diseases. The table is adapted from the manuscript Strausz et al. (2020) 
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic 
health.
4.2.1 FINRISK, Heath 2000 Survey, Botnia (Study I)
The population-based FINRISK surveys are independent random samples drawn 
from the population registry of six geographic areas of Finland (North Karelia, 
Kuopio, Lapland, Oulu, Turku/Loimaa and Helsinki/Vantaa) and stratified 
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according to gender, 10-year age group and study area. The study included a 
questionnaire in addition to a clinical examination at which a blood sample was 
drawn (189). Participants from different survey years (1992, 1997, 2002 or 2007) 
were pooled together.
The total sample size for all FINRISK surveys was 29,257 and participants 
who had missing information (N=7) or type 1 diabetes (T1D) (N=297) were excluded 
from the study. Thus, the total sample size was 28,953 where 13,792 male and 15,161 
female participants aged 24–74 years at baseline were included in the analyses. 
Of these participants, 1214 (4.2%) had OSA.
The Health 2000 Survey (H2000) is a comprehensive combination of a health 
interview and a health examination survey. The study was based on a nationally 
representative sample of 8,028 persons aged ≥30 years living in mainland Finland 
(190). After excluding participants who had missing information (N=1,331) or T1D 
(N=92), the final dataset consisted of 6605 participants, 2940 men and 3707 
women. Out of this cohort 235 (3.6%) participants were diagnosed with OSA.
The Botnia Study was established in 1990 to investigate familial clustering 
of diabetes in the Ostrobothnia region in western Finland, and the non-diabetic 
participants have been prospectively followed (191). The population-based PPP-
Botnia Study was conducted in the same geographical area (192). From the Botnia/
PPP Botnia Studies (referred to collectively as the Botnia study), we included 1,405 
patients with T2D, 735 men and 670 women. In this cohort, 119 participants (8.5%) 
had an OSA diagnosis.
During the follow-up of the study cohorts, data for hospitalisations and causes 
of death were obtained from the Finnish National Hospital Discharge Registry 
and the Causes of Death Registry. Follow-up for FINRISK ended on 31 December 
2014, for H2000 on 31 December 2013 and for Botnia on 31 December 2015.
In the FINRISK cohorts, the follow-up was up to 22 years (median 12.9 
years, interquartile range ((IQR) 8.5–17.9) and in the H2000 cohort the follow-up 
was up to 14.5 years (median 13.9, IQR 13.6–14.2). In the the Botnia study, the 
follow-up was up to 25 years (median 14.7 years, IQR 10.2–21.4). Altogether, we 
had 523,372 person-years of follow-up.
4.2.2 FinnGen (Study II-III)
The FinnGen study (www.finngen.fi/en) is a remarkable biobank study that aims 
to genotype 500,000 Finns. The data includes prospective and retrospective 
epidemiological and disease-based cohorts as well as hospital biobank samples. 
The FinnGen study combines genomic data with longitudinal registry data that 
records health care events over the entire lifespan of an participant. This includes 
data from the National Hospital Discharge Registry (available from 1968), Causes 
of Death Registry (available from 1969), the National Infectious Diseases Registry 
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(available from 1995), Cancer Registry (available from 1953) and Medication 
Reimbursement Registry (available from 1995), all utilizing unique national 
personal identification codes. Registry data was available from the beginning of 
the registry until 31.12.2018, (Figure 5).  In study II, the data from FinnGen Data 
Freeze 5 consisted of 218,792 individuals. Participants who had ICD-code G47 
(Sleep disorders) were excluded from the controls (N=837) and thus the remaining 
sample size was 217,955 participants. Of these, 94,799 were men and 123,156 
were women, including 16,716 (7.7%) which were OSA patients. In study III, the 
data consisted of 260,405 FinnGen Data Freeze 6 participants, 113,344 men and 
147,061 women, including 20,279 OSA patients. From that data individuals with 
polymerase chain reaction (PCR)-validated COVID-19 diagnosis were derived 
(N=445). 
4.2.2.1 Data security in FinnGen
The FinnGen study manages healthcare registry and genomic data without 
compromising the privacy and integrity of participants. A key feature of the project 
is that the pseudonymized individual-level data is released into a secure, carefully 
monitored environment with limited access rights that does not allow internet 
access nor download of the  individual-level data to local environments. The 
members of the research project only handle data that has been pseudonymized 
and no strong identifiers are linked to the data (e.g. social security numbers, emails, 
addresses). In addition, very rare clinical endpoints  (less than 5 occurrences) are 
removed, and the time of events is randomized (+- 15 days). 
The University of Helsinki is responsible for the FinnGen research project 
and is the official data controller of the study. In addition, the FinnGen study 
has nominated persons responsible for information security and data protection, 
whose job is to supervise the information security and data protection of the 
research subjects. 
The FinnGen information technology environment and data protection 
practices are regularly reviewed by impartial third-party service providers. The 




















































































































































































































































































4.2.3 International replication cohorts (Study II)
The UK Biobank (UKBB, https://www.ukbiobank.ac.uk/), Estonian Biobank 
(ESTBB) www.biobank.ee) and All New Diabetics in Scania (ANDIS, http://andis.
ludc.med.lu.se/) cohorts were utilized to replicate our GWAS results and were used 
in forming a meta-analysis concerning the main results of Study II. Data with full 
phenotype and genotype information and individuals passing genotyping quality 
control were included in the analyses. 
The UKBB is a large national and international health resource, with the aim 
of enhancing the prevention, diagnosis, and treatment of a wide range of serious 
and life-threatening illnesses. UKBB recruited 500,000 people in 2006-2010 from 
across the United Kingdom. OSA diagnosis was based on ICD-10: G47.3. The study 
sample in the UKBB included 4,471 OSA cases and 403,723 controls. 
The ESTBB is a population-based biobank of the Estonian Genome Center at 
the University of Tartu. The cohort size is currently close to 150,000 participants. 
Patients were selected by ICD-10: G47.3. For additional confirmation of the 
diagnosis, treatment service codes from the Health Insurance Fund were also 
used. The study sample in the ESTBB included 4,930 OSA patients and 61,056 
age- and sex-matched controls.
The ANDIS study aims to recruit all incident cases of diabetes within Scania 
County in Southern Sweden. All health care providers in the region were invited; 
the current registration covered 14,625 patients. OSA was defined by ICD-10: G47.3. 
The study sample included 947 OSA patients and 9,829 controls.  
4.2.4 Hospital District of Helsinki and Uusimaa hospital’s patients 
records (Study II and III)
For the validation of OSA diagnoses, 1,000 OSA patients were randomly selected 
among patients who were treated in Hospital District of Helsinki and Uusimaa 
(HUS) during the years 2008-2011 and 2016-2019. The diagnoses were derived 
from HUS’s Hospital Discharge Registry and confirmed utilizing individual-level 
medical records.  
Treatment information concerning the association between OSA and 
COVID-19 was collected from the patient records of the Heart and Lung Center 
or Department of Oral and Maxillofacial Diseases, Helsinki University Hospital 
(HUH), Finland. 
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4.3 Genotyping and imputation (Study II)
The FinnGen study genotyped samples with Illumina and Affymetrix arrays 
(Thermo Fisher Scientific, Santa Clara, California, USA). Genotype calls were made 
with the GenCall and zCall -algorithms for Illumina and the AxiomGT1 algorithm 
for Affymetrix chip data. Genotyping data produced with previous chip platforms 
were lifted over to human reference genome build version 38. Samples with sex 
discrepancies, missingness (>5%), excess heterozygosity (+-4 standard deviation 
(SD)) and non-Finnish ancestry were removed. Variants with high missingness 
(>2%), deviation from Hardy–Weinberg equilibrium (P<1.0×10−6) and low minor 
allele count (<3) were removed. Pre-phasing of genotyped data was performed 
with Eagle 2.3.5 (https://data.broadinstitute.org/alkesgroup/Eagle/) with default 
parameters, excluding the number of conditioning haplotypes which was set to 
20,000. Imputation was done using the population-specific Sequencing Initiative 
Suomi (SISu) v3 imputation reference panel with Beagle 4.1 (version 08Jun17.
d8b, https://faculty.washington.edu/browning/beagle/b4_1.html) as described in 
the following protocol: [dx.doi.org/10.17504/protocols.io.nmndc5e]. The SISu v3 
imputation reference panel was developed using high-coverage (25–30×) whole-
genome sequencing data generated at the Broad Institute of MIT and Harvard 
and at the McDonnell Genome Institute at Washington University, USA and was 
jointly processed at the Broad Institute. The variant callset was produced with 
genomic analysis toolkit (GATK) HaplotypeCaller algorithm by following GATK 
best-practices for variant calling. Genotype-, sample- and variant-wise quality 
control was applied in an iterative manner by using the Hail framework v0.1 
(https://Github.com/hail-is/hail/releases/tag/0.2.13, http://Doi.org/10.5281/
zenodo.2646680). 
The resulting high-quality whole genome sequence data for 3775 individuals 
were phased with Eagle 2.3.5 as described above. Post-imputation quality control 
involved excluding variants with imputation quality score (INFO) <0.7.
4.4 Statistical analyses
To study OSA comprehensively and accurately, a wide range of statistical methods 
were utilized. These include basic analyses, but also the latest statistical genetics 
approaches in addition to longitudinal analyses.  
4.4.1 General analyses
To test and evaluate the differences in baseline demographics and clinical 
characteristics, χ2 tests were used, unless the expected cell size was ≤5 where 
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Fisher’s exact test was used instead. For continuous variables, Student’s t-test 
was utilized. P<0.05 was considered statistically significant, and all tests were 
two sided. Logistic regression analysis was used to calculate odds between the 
dependent binary variables and the sets of independent variables such as 
age, sex and OSA comorbidities. 
4.4.2 Prospective analyses 
The associations between OSA and incident CHD events, DKD events and T2D 
were tested using Cox proportional hazards models implemented in the R package 
Survival. Age at onset of OSA was used as a time-dependent covariate in the 
analyses and age was used as the timescale. In such a Cox model, a person 
contributes to the model only for his/her at-risk period (i.e., for a certain age 
range). During that period, the individual could become an OSA case, and before 
could have a T2D diagnosis or a cardiovascular event. In this case, using OSA as 
a time-dependent covariate, a participant contributes to the model as a non-OSA 
case until the age at OSA diagnosis, and as an OSA case for the remainder of his/
her at-risk period. Prevalent cases were excluded from the Cox regression analyses 
and the assumptions of the models were tested with the cox.zph-function using 
scaled Schoenfeld residuals. 
In our FINRISK unadjusted model for CHD, we used age, gender, 
geographical area and cohort year as covariates. In the adjusted model, in addition 
to aforementioned factors, traditional risk factors were used as covariates for 
cardiovascular events: HDL, total cholesterol, current cigarette smoking, BMI, 
hypertension (defined as a measured blood pressure of at least 140/90 mm Hg 
or the use of antihypertensive medications), prevalent T2D and family history of 
stroke or myocardial infarction.
In the unadjusted analysis, similar to CHD, the association between OSA 
and T2D was adjusted for age, gender, geographical area and cohort year. In the 
adjusted model, also BMI was used as a covariate. Among patients with T2D with 
the endpoint of DKD, the model was adjusted for BMI and hypertension.
In the H2000 cohort, it was not possible to adjust the model for family history 
of stroke or myocardial infarction because that information was not determined 
in the study. Otherwise, the Cox time-dependent hazards model was adjusted for 
the same risk factors as mentioned previously.
The evidence from the FINRISK and H2000 cohorts were combined to 
analyse CHD and T2D. To analyse T2D complications in more detail, the Botnia 
study was used as a third cohort. The results were combined using fixed-effect 
meta-analysis.
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4.4.3 Genome-wide association testing
A GWAS is a method used in genetics research to link specific genetic variations 
with certain diseases. The approach requires examining the genomes from 
several individuals and looking for genetic markers which may be used to predict 
the presence of a disease. Finding such genetic markers can lead to a better 
understanding of how genes contribute to disease and the results may guide the 
development of prevention and treatment strategies (193). 
A total of 218,792 samples from FinnGen Data Freeze 5 with 2,925 
disease endpoints were analyzed using scalable and accurate implementation 
of generalized mixed model (SAIGE), which uses saddle point approximation to 
calibrate unbalanced case-control ratios. In addition, this method reduces the 
risk for type 1 error (194). 
Analyses were adjusted for current age or the age at death, sex, genotyping 
chip, genetic relationship and first the 10 principal components (PCs). For OSA, 
a GWAS was performed in a similar manner (N=217,955, including 16,761 OSA 
patients and 201,194 controls), but was also adjusted for BMI (N=159,731, including 
12,759 OSA patients and 146,972 controls).
For the replication of the FinnGen OSA GWAS results, evidence from the 
UKBB, ESTBB and ANDIS cohorts were merged. The results were combined using 
inverse-variance weighted fixed-effect meta-analysis using beta estimates and 
beta standard errors with the R package Metagen as implemented in R version 
V.4.0.2 (www.r-project.org). The merged data consisted of 10,348 OSA cases and 
474,608 controls. 
4.4.4 Phenome-wide association testing
Phenome-wide association studies (PheWASes) can identify pleiotropy, or the 
finding of multiple independent phenotypes associated with a single genetic 
variant. GWAS and PheWAS approaches are complementary, with the ability to 
replicate and validate the other's findings (195, 196). A PheWAS was performed 
using the FinnGen data which examined the associations between the lead SNPs 
in OSA GWASes and 2,925 disease endpoints. The PheWAS method was also 
utilized to study the association between lead variants and drug purchases. 
4.4.5 Meta-analyses
To combine and generalize the results of our studies we used meta-analyses. 
Fixed-effect meta-analysis was utilized if the heterogeneity between studies was 
not statically significant (P > 0.1). Otherwise, random-effect meta-analysis was 
implemented with the restricted maximum likelihood method (REML) to estimate 
the heterogeneity of variance (197). 
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4.4.6 Polygenic risk score and Mendelian randomization 
Polygenic risk scores (PRSes) summarize the effects of genome-wide genetic 
markers to measure the genetic liability of a trait or a disorder. Studies based 
on PRSes have revealed promising results when predicting complex traits and 
diseases. The results may be utilized in early diagnosis of disease, risk stratification, 
and also in disease prevention (198, 199). 
PRSes for BMI were calculated using summary statistics for 996,250 variants 
(9).  The posterior effect sizes were calculated utilizing the PRS-continuous 
shrinkage (CS) method. PRS-CS is a polygenic prediction approach which infers 
posterior effect sizes of SNPs using genome-wide association summary statistics 
in addition to an external LD reference panel (200). 
PRSes for the OSA replication were calculated using dosage-weighted beta-
estimates for each lead variant (P<5×10−8, 5 variants). The scores were generated 
using Plink2 (https://www.cog-genomics.org/plink/2.0/) in the FinnGen data and 
the weights from FinnGen were projected to the UKBB individual-level data.
Mendelian randomization (MR) is a method which uses genetic variation 
to improve causal assumptions in observational studies. A genetic variant 
linked with the exposure of interest (a genetic instrument) is utilized to test the 
causal relationship between exposure and outcome. If the association exists, a 
causal relationship can be assumed. It is assumed, in contrast to observational 
associations, that the genetic variant is not subject to issues of reverse causation 
and/or confounding (201). The assumptions of MR include the following: 1) the 
genetic instrument is associated with the exposure of interest, 2) the genetic 
instrument is independent of factors that confound the association of the exposure 
and the outcome and 3) the genetic instrument is independent of the outcome, 
given the exposure and the confounders (202).
MR analysis was performed to investigate the causality between BMI and OSA 
using independent BMI SNPs (9). A genetic variant associated with the exposure 
of interest was used to test the causal relationship with the exposure (BMI) and 
outcome (OSA).
4.4.7 Genetic correlations
Genetic correlation between traits is a measure of the genetic components shared 
by traits. To estimate genetic correlations, SNP-based heritability and tissue-
specific SNP-heritability LD score regression (LDSC) was utilized. The approach 
quantifies the contribution of each variant by examining the relationship between 
test statistics and LD (203). SNP heritability is defined as the fraction of the 
phenotypic variance explained by the additive effects of a given set of genetic 
variants (204, 205).  In calculating LD scores, a subset of the 1000 Genomes 
Project derived from European ancestry individuals was used (181). To restrict 
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to a set of common, well-imputed variants, only those SNPs in the HapMap 3 
reference panel were retained (206). 
Summary statistics from the FinnGen data were used to study genetic 
correlations between OSA, BMI, hypertension, T2D, CHD, stroke, depression, 
hypothyroidism, asthma and IRD. For sleep traits, summary statistics derived 
from the UKBB data were used, where study subjects self-reported snoring (207), 
sleep duration, sleepiness (208) and chronotype (209). 
Sleep efficiency (sleep duration divided by the time between the start and 
end of the first and last nocturnal inactivity period, respectively) was based on 
accelerometer-derived measures (210).  
For tissue-specific SNP-heritability a method (211, 212) combining data from 
Encyclopaedia of DNA Elements (ENCODE, https://www.encodeproject.org/) and 
the Genotype-Tissue Expression (GTEx, https://gtexportal.org/home/) resources 
was used.
4.4.8 Gene based analysis
Gene-based tests were performed using multi-marker analysis of genomic 
annotation (MAGMA) as implemented in the Functional mapping and annotation 
platform. Analyses provide aggregate associated P-values based on all variants 
located within a gene and its regulatory region using information from 18 biological 
data repositories and tools (213). This analysis included a gene-based test to detect 
significant SNPs associated with OSA using FinnGen OSA summary statistics.
4.5 Ethics statement
FINRISK data are stored in THL Biobank which distributes them to researchers 
on the basis of written applications. The Coordinating Ethical Committee of the 
Helsinki and Uusimaa Hospital District approved our THL Biobank request with 
the decision # 238/13/03/00/2014. The H2000 protocol was approved by the 
Ethical Committee of the National Public Health Institute (decision number 8/99). 
The Botnia Study protocols were approved by the Ethics Committee of the Helsinki 
University Central Hospital, Finland, with the decision #574/E5/03.
Patients and controls in FinnGen provided informed consent for biobank 
research, based on the Finnish Biobank Act. Alternatively, older research cohorts 
collected prior to the start of the FinnGen study (August 2017), were collected 
based on study-specific consents and later transferred to the Finnish biobanks after 
approval by Valvira, the National Supervisory Authority for Welfare and Health. 
Recruitment protocols followed the biobank protocols approved by Valvira. The 
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5 RESULTS  
5.1 Validation of obstructive sleep apnoea diagnosis
OSA diagnosis was validated using HUS’s Hospital Discharge Registry by collecting 
information from 1,000 patients and comparing the registry data to the patient’s 
medical records. OSA diagnosis had a validity of over 98% positive predictive 
value (PPV), (Figure 6). 
Figure 6. Obstructive sleep apnoea (OSA) diagnosis was validated using Hospital District of Helsinki 
and Uusimaa (HUS) Hospital Discharge Registry, collecting information from 1,000 patients and 
comparing the registry data to the patient medical records. OSA diagnosis has a validity of over 98% 
positive predictive value (PPV) when using the International Classification criteria for Sleep Disorders 
for OSA (44). The figure is adapted from the manuscript Strausz et al. (2020) Genetic analysis of 
obstructive sleep apnoea discovers a strong association with cardiometabolic health.
Diagnosis of OSA was confirmed using the International Classification 
criteria for Sleep Disorders, which requires either signs/symptoms (e.g. 
associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory 
disturbance, or observed apnoea) or associated medical or psychiatric disorder 
(i.e. hypertension, coronary artery disease, atrial fibrillation, congestive heart 
failure, stroke, diabetes, cognitive dysfunction, or mood disorder) coupled with 
five or more predominantly obstructive respiratory events per hour. Alternatively, 
a frequency of obstructive respiratory events 15 per hour satisfies the criteria, even 
in the absence of associated symptoms or disorders (44).
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5.2 Associations between obstructive sleep apnoea 
and incident cardiometabolic diseases
To analyse the comorbidity of OSA and CHD, T2D outcomes and T2D complications, 
longitudinal data from three population-based cohorts were combined including 
36,963 participants with 1,568 (4.2%) patients with OSA. These cohorts included 
FINRISK (N=28,953) with a follow-up of up to 22 years (median 12.9 years, IQR 
8.5–17.9), H2000 (N=6,605) with a median follow-up of 13.9 years (IQR 13.6–14.2) 
and patients with T2D from the Botnia Study (N=1,405) with a median follow-up 
of 15.3 years (IQR 10.8–21.3). Altogether the sample included 6,248 patients with 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The association between OSA and the risk of incident CHD was evaluated. The 
unadjusted model was adjusted for age, sex and geographical region. OSA diagnosis 
was associated with an increased risk of CHD (hazard ratio (HR)=1.54, 95% 
confidence interval (CI) 1.28 to 1.86, P=4.43×10−6). 
Table 6. Association between obstructive sleep apnoea and incident coronary heart disease events
Number of events/
Subjects at risk
Unadjusted model Adjusted model
All HR [95% CI] P HR [95% CI] P
FINRISK 2129/27948 1.43 [1.17-1.75] 7.34×10-4 1.25 [1.01-1.54] 0.037
H2000 565/6267 2.13 [1.40-3.24] 4.08×10-4 1.91 [1.25-2.92] 2.80×10-3
Combined 2694/34215 1.54 [1.28-1.86] 4.43×10-6 1.36 [1.12-1.64] 1.40×10-3
Men
FINRISK 1480/13066 1.33 [1.06-1.67] 0.015 1.18 [0.94-1.49] 0.157
H2000 306/2748 1.81 [1.13-2.91] 0.014 1.57 [0.97-2.55] 0.069
Combined 1786/15814 1.41 [1.15-1.73] 1.10×10-3 1.25 [1.01-1.54] 0.039
Women
FINRISK 649/14882 1.99 [1.24-3.19] 4.11×10-4 1.66 [1.03-2.68] 0.036
H2000 259/3519 4.12 [1.68-10.18] 2.06×10-3 4.03 [1.62-10.01] 2.64×10-3
Combined 908/18401 2.33 [1.53-3.53] 7.19×10-5 2.01 [1.31-3.07] 1.20×10-3
The FINRISK unadjusted model is adjusted for age, cohort year, geographical area and gender. 
The adjusted model is adjusted for high density lipoprotein (HDL) and total cholesterol (CHOL), 
current cigarette smoking, body mass index (BMI), hypertension, prevalent type 2 diabetes and 
family history of stroke or myocardial infarction in addition to covariates of the unadjusted model. 
The Health 2000 Survey (H2000) unadjusted model is adjusted for geographical area and gender. 
H2000-adjusted model is adjusted for HDL and CHOL, current cigarette smoking, BMI, hypertension, 
and prevalent type 2 diabetes in addition to covariates of the unadjusted model. HR=hazard ratio, 
CI=confidence interval. The table is adapted from the manuscript Strausz et al. (2018) Obstructive 
sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-
based study in Finland.
In addition, the model was adjusted for CHD risk factors including age, sex, 
region, HDL and total cholesterol, current cigarette smoking, BMI, hypertension, 
T2D baseline and family history of stroke or myocardial infarction. As a result, 
this association was somewhat attenuated (adjusted HR=1.36, 95% CI 1.12 to 1.64, 
P=1.40×10−3). 
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The estimates were concordant across the cohorts and were slightly higher 
for women (adjusted HR=2.01, 95% CI 1.31 to 3.07, P=1.20×10−3) than for men 
(adjusted HR=1.25, 95% CI 1.01 to 1.54, P=0.039), (Table 6). OSA did not, however, 
associate with stroke risk (adjusted HR=0.99, 95% CI 0.75 to 1.33, P=0.98). 
5.2.2 The effect of obstructive sleep apnoea on type 2 diabetes 
and its complications
The role of OSA as a risk factor for T2D was evaluated, showing an association 
with increased risk among individuals with OSA (HR=2.52, 95% CI 2.16 to 2.93, 
P=1.91×10−32). The risk was somewhat attenuated after further adjustment for BMI 
(adjusted HR=1.48, 95% CI 1.26 to 1.73, P=9.11×10−7) revealing a corresponding 
effect in both cohorts. Similarly, the association was more notable in women 
(adjusted HR=1.63, 95% CI 1.20 to 2.23, P=2.20×10−3) than in men (adjusted HR 
=1.44, 95% CI 1.27 to 2.21, P=9.62×10−5), (Table 7).
Table 7. Association between obstructive sleep apnoea and the population for incident type 2 diabetes
Number of events/ 
Subjects at risk
Unadjusted model Adjusted model
All HR [95% CI] P HR [95% CI] P
FINRISK 2435/27161 2.40 [2.03-2.84] 1.53×10-24 1.38 [1.16-1.64] 2.74×10-4
H2000 455/6181 3.18 [2.20-4.59] 7.03×10-10 2.05 [1.42-2.97] 1.41×10-4
Combined 2890/33342 2.52 [2.16-2.93] 1.91×10-32 1.48 [1.26-1.73] 9.11×10-7
Men
FINRISK 1372/12880 2.21 [1.81-2.69] 2.55×10-15 1.28 [1.05-1.57] 0.017
H2000 257/2772 3.65 [2.44-5.44] 2.23×10-10 2.27 [1.51-3.41] 8.08×10-5
Combined 1629/15652 2.43 [2.04-2.90] 4.16×10-23 1.44 [1.27-2.21] 9.62×10-5
Women
FINRISK 1063/14281 3.14 [2.28-4.33] 3.12×10-12 1.65 [1.18-2.29] 2.98×10-3
H2000 198/3409 2.16 [0.80-5.87] 0.13 1.48 [0.55-4.02] 0.44
Combined 1261/17690 3.03 [2.23-4.12] 1.25×10-15 1.63 [1.20-2.23] 2.20×10-3
The FINRISK unadjusted model is adjusted for age, cohort year, geographical area and gender. The 
adjusted model is adjusted for body mass index (BMI) in addition to covariates of the unadjusted 
model. The Health 2000 Survey (H2000) unadjusted model is adjusted for geographical area and 
gender. The adjusted model is adjusted for BMI in addition to covariates of the unadjusted model. 
HR=hazard ratio, CI=confidence interval. The table is adapted from the manuscript Strausz et al. 
(2018) Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a 
longitudinal population-based study in Finland.
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The Botnia cohort was included in the meta-analysis to study T2D 
complications more in detail as H2000 lacked incident DKD events among patients 
with OSA. OSA associated with increased risk for DKD (HR=2.16, 95% CI 1.40 
to 3.34, P=5.00×10−4) among T2D patients. After adjusting for the known risk 
factors for DKD (BMI and hypertension), the estimate was slightly attenuated 
(adjusted HR=1.75, 95% CI 1.13 to 2.71, P=0.013). The effects were similar in both 
cohorts, (Table 8). 
Table 8. Associations between obstructive sleep apnoea and incident type 2 diabetes complications
Number of events/ 
Subjects at risk
Unadjusted model Adjusted model
DKD HR [95% CI] P HR [95% CI] P
FINRISK 147/3932 2.15 [1.27-3.62] 4.10×10-3 1.72 [1.01-2.93] 0.044
Botnia 91/1380 2.19 [1.003-4.79] 0.049 1.80 [0.82-3.96] 0.143
Combined 238/5312 2.16 [1.40-3.34] 5.00×10-4 1.75 [1.13-2.71] 0.013
CHD HR [95% CI] P HR [95% CI] P
FINRISK 640/3710 1.44 [1.07-1.95] 0.016 1.40 [1.04-1.90] 0.028
H2000 152/761 1.46 [0.74-2.82] 0.272 1.46 [0.74-2.89] 0.274
Botnia 236/1253 1.18 [0.60-2.31] 0.630 1.07 [0.54-2.11] 0.840
Combined 1028/5724 1.40 [1.10-1.81] 8.50×10-3 1.36 [1.05-1.76] 0.019
The FINRISK unadjusted models are adjusted for age, cohort year, geographical area and gender. 
The Health 2000 Survey (H2000) unadjusted models are adjusted for age, geographical area and 
gender. The Botnia unadjusted models are adjusted for age and gender. The adjusted models for 
diabetic kidney disease (DKD) are adjusted for body mass index (BMI) and hypertension in all 
cohorts in addition to covariates of the unadjusted model. The FINRISK adjusted model for coronary 
heart disease (CHD) is adjusted for high density lipoprotein (HDL) and total cholesterol (CHOL), 
current cigarette smoking, BMI, hypertension and family history of stroke or myocardial infarction 
in addition to covariates of unadjusted model. The H2000 and Botnia adjusted models for CHD 
are adjusted for HDL and CHOL, current cigarette smoking, BMI and hypertension in addition to 
covariates of the unadjusted model. HR=hazard ratio, CI=confidence interval. The table is adapted 
from the manuscript Strausz et al. (2018) Obstructive sleep apnoea and the risk for coronary heart 
disease and type 2 diabetes: a longitudinal population-based study in Finland.
OSA alone was associated with an increased risk for CHD by 1.40-fold (95% CI 
1.10 to 1.81, P=8.50×10−3) among patients with T2D. The result was almost the same 
after adjusting for the following risk factors: HDL and total cholesterol, current 
cigarette smoking, BMI, hypertension and family history of stroke or myocardial 
infarction (adjusted HR=1.36, 95% CI 1.05 to 1.76, P=0.019), (Table 8).
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5.2.3 The association between obstructive sleep apnoea and 
mortality risk
OSA’s role as an independent risk factor for all-cause mortality was also 
investigated. OSA was associated with an increased risk for mortality (HR=1.18, 
95% CI 1.00 to 1.40, P=0.057), but this risk was attenuated after adjusting for other 
confounding factors. Among T2D patients, OSA was related to increased mortality 
risk (HR=1.40, 95% CI 1.21 to 1.62, P=2.03×10−6). This estimate also remained 
significant after adjustments (HR=1.35, 95% CI 1.06 to 1.71, P=0.016), (Table 9). 
Table 9. Associations between obstructive sleep apnoea and all-cause mortality among general 
population and type 2 diabetes (T2D) individuals
Number of events/ 
Subjects at Risk
Unadjusted model Adjusted model
General 
population
HR [95% CI] P HR [95% CI] P
FINRISK 3228/28666 1.08 [0.89-1.31] 0.438 1.01 [0.83-1.22] 0.949
H2000 1286/6498 1.65 [1.14-2.39] 7.91×10-3 1.74 [1.20-2.52] 3.68×10-3
Combined 4514/35164 1.18 [1.00-1.40] 0.057 1.13 [0.95-1.34] 0.161
T2D HR [95% CI] P HR [95% CI] P
FINRISK 719/3940 1.37 [1.01-1.84] 0.041 1.23 [0.91-1.67] 0.179
H2000 284/820 1.35 [0.68-2.71] 0.390 1.48 [0.74-2.98] 0.267
Botnia 348/1309 1.84 [1.14-2.99] 1.44×10-4 1.62 [1.00-2.65] 0.052
Combined 1351/6069 1.40 [1.21-1.62] 2.03×10-6 1.35 [1.06-1.71] 0.016
The FINRISK unadjusted models are adjusted for age, cohort year, geographical area and gender. 
The Health 2000 Survey (H2000) unadjusted models are adjusted for age, geographical area and 
gender. The Botnia unadjusted models are adjusted for age and gender. The FINRISK adjusted 
model is adjusted for high density lipoprotein (HDL) and total cholesterol (CHOL), current cigarette 
smoking, body mass index (BMI), hypertension and family history of stroke or myocardial infarction 
in addition to covariates of unadjusted model. The H2000 and Botnia adjusted models are adjusted 
for HDL, CHOL, current cigarette smoking, BMI and hypertension in addition to covariates of the 
unadjusted model. Adjusted models for general population are also adjusted for prevalent type 
2 diabetes. HR=hazard ratio, CI=confidence interval. The table is adapted from the manuscript 
Strausz et al. (2018) Obstructive sleep apnoea and the risk for coronary heart disease and type 2 
diabetes: a longitudinal population-based study in Finland.  
OSA was associated with increased risk for all-cause mortality among 
patients with T2D but was not significantly associated with increased risk for 
all-cause mortality in the general population. The main cause of mortality was 
CHD both in T2D patients (33.8%) and in the general population (30.8%).
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5.3 Genetic studies
To estimate the strengths of genetic associations between OSA and OSA-related 
comorbidities, data from 217,955 individuals who participated in the FinnGen 
project were utilized. 16,761 (7.7%) had an OSA diagnosis and 10,557 (63%) cases 
were male. The diagnoses were derived from ICD-codes in the Finnish National 
Hospital Discharge Registry and from the Causes of Death Registry. Baseline 
characteristics of the FinnGen participants and odds ratios (ORs) for OSA-
associated comorbidities are presented in Table 10. 
Table 10. Baseline characteristics and previously known obstructive sleep apnoea (OSA) comorbidities 
in OSA and non-OSA individuals 
   All Non-OSA OSA OR [95% CI] P
N=217955 N=201194 N=16761
Male (N, %) 94799 (43.5) 84242 (41.9) 10557 (63.0) 2.26 [2.19-2.34] < 2.00 × 10−16
Female (N, %) 123156 (56.5) 116952 (58.1) 6204 (37.0)
Age (mean in 
years, SD) 52.4 (17.5) 51.8 (17.7) 58.9 (13.3) 1.02 [1.02-1.03] < 2.00 × 10
−16





(mean kg/m2, SD) 27.25 (5.34) 26.87 (5.02) 31.72 (6.74) 1.15 [1.15-1.16] < 2.00 × 10
−16
Hypertension 
(N, %) 55678 (25.5) 47549 (23.6) 8129 (48.5) 2.44 [2.36-2.53] < 2.00 × 10
−16
T2D (N, %) 29054 (13.3) 23932 (11.9) 5122 (30.6) 2.60 [2.50-2.70] < 2.00 × 10−16
CHD (N, %) 20925 (9.6) 18495 (9.2) 2430 (14.5) 1.11 [1.06-1.17] 1.04 × 10−5
Stroke (N, %) 11671 (5.4) 10414 (5.2) 1257 (7.5) 1.10 [1.03-1.17] 3.29 × 10−3
Depression (N, %) 23160 (10.6) 20094 (10.0) 3066 (18.3) 2.56 [2.45-2.67] < 2.00 × 10−16
Hypothyroidism 
(N, %) 26228 (12.0) 23384 (11.6) 2844 (17.0) 1.85 [1.77-1.94] < 2.00 × 10
−16
Asthma (N, %) 20520 (9.4) 17358 (8.6) 3162 (18.9) 2.58 [2.47-2.69] < 2.00 × 10−16
IRD (N, %) 12961 (5.9) 11555 (5.7) 1406 (8.4) 1.48 [1.39-1.57] < 2.00 × 10−16
Age and body mass index (BMI) were measured at the time that the biobank sample was given. BMI 
was measured for 159,731 individuals including 12,759 OSA cases and 146,972 controls. T2D=type 
2 diabetes, CHD=coronary heart disease, IRD=inflammatory rheumatic diseases, OR=odds ratio, 
CI=confidence interval, SD=standard deviation. The table is adapted from the manuscript Strausz 
et al. (2018) Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: 
a longitudinal population-based study in Finland.
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5.3.1 Genome-wide findings and heritability
In the GWAS, five novel genetic loci were found to associate with OSA (P<5.0×10−8), 
(Table 11, Figure 7a). In addition, the heritability of OSA in the FinnGen study 
was estimated to be 0.08 (95% CI 0.06 to 0.11) before and 0.06 (95% CI 0.04 to 
0.08) after adjustment  for BMI.
The lead variant in chromosome 16 was rs9937053, an intronic variant in the 
gene Fat mass and obesity-associated protein (FTO), P=4.3×10−16. In chromosome 
12, the lead variant was rs10507084, near Rhabdomyosarcoma 2 associated 
transcript (RMST)/ NEDD1 gamma-tubulin ring complex targeting factor 
(NEDD1), P=2.8×10−11. RMST, a long non-coding RNA, was the nearest gene and 
NEDD1 the nearest protein coding gene. On chromosome 10, the lead variant was 
rs185932673, an intronic variant in Calcium/calmodulin-dependent protein kinase 
1D (CAMK1D), P=2.4×10−8. In chromosome 9, the lead variant was rs4837016 
near GTPase activating protein and VPS9 domains 1 (GAPVD1), P=1.5×10−8 and 
in chromosome 2, the lead variant rs10928560 was near C-X-C motif chemokine 
receptor 4 (CXCR4), P=2.8×10−8. Four out of five of these OSA-associated lead 
variants have also been previously associated with BMI (P<0.01) (214-216), with 
the exception of rs10507084 at the RMST/NEDD1 locus. Conditional analyses of 
the associated loci did not suggest any additional associations. 
Adjusting for BMI did not affect the association for variant rs10507084 (Table 
11, Figure 7b), (ORunadjusted=1.11, 95% CI 1.08 to 1.15, P=2.8×10
−11 vs. ORBMI adjusted=1.12, 
95% CI 1.08 to 1.17, P=9.7×10−11) suggesting a BMI-independent mechanism for 
rs10507084 in OSA predisposition. As a sensitivity analysis we conducted a GWAS 
where individuals with snoring (ICD-10: R06.5) were removed, after which 197,797 
individuals remained in the control group. No new associations were observed, 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 7. a) Manhattan plot for the genome-wide association study (GWAS) of obstructive sleep 
apnoea (OSA) including 16,761 OSA cases and 201,194 controls. For each genetic variant, the 
x-axis shows chromosomal position, while y-axis shows the −log10(P) value. The horizontal line 
indicates the genome-wide significance threshold of P=5×10−8. Five genetic loci were identified 
at a genome-wide significant level. CXCR4=C-X-C motif chemokine receptor 4, GAPVD1=GTPase 
activating protein and VPS9 domains 1, CAMK1D=Calcium/calmodulin-dependent protein kinase 1D, 
RMST=Rhabdomyosarcoma 2 associated transcript / NEDD1=NEDD1 gamma-tubulin ring complex 
targeting factor, FTO=Fat mass and obesity-associated protein.
b) Manhattan plot for the GWAS of OSA after body mass index (BMI) adjustment including 12,759 
OSA cases and 146,972 controls. For each genetic variant, the x-axis shows chromosomal position, 
while y-axis shows the −log10(P) value. The horizontal line indicates the genome-wide significance 
threshold of P=5×10−8. One genetic locus was identified at a genome-wide significant level. The figure 
is adapted from the manuscript Strausz et al. (2020) Genetic analysis of obstructive sleep apnoea 
discovers a strong association with cardiometabolic health.
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5.3.1.1 Replication 
To replicate the lead variants associated with OSA, additional and comparable 
cohorts (UKBB, ANDIS and ESTBB) were used. The results were pooled using 
inverse-variance weighted fixed effect meta-analysis. These independent datasets 
supported the role of the FTO and GAPVD1 loci in OSA (P<0.05), (Table 12). 
Table 12. Replication of the lead variants  





























10 rs185932673 OR=0.96 [0.73-1.26]
P=0.74























Inverse-variance weighted meta-analysis combining the results of the replication cohorts of the 
main FinnGen findings considering obstructive sleep apnoea (OSA). CHR=chromosome, OR=odds 
ratio, [95% confidence interval], UKBB = UK Biobank, ANDIS = All New Diabetics in Scania, ESTBB 
= Estonian Biobank. The table is adapted from the manuscript Strausz et al. (2020) Genetic analysis 
of obstructive sleep apnoea discovers a strong association with cardiometabolic health.
PRSes were calculated using the lead variants from our study to predict 
OSA in the UKBB's individual-level data. This revealed an association with OSA 
risk, where the individuals in the highest OSA PRS quintile had a modest 1.24-
fold (95% CI 1.15 to 1.33, P=6.89×10−9) increased OSA risk compared with the 
lowest quintile after adjusting for birth year, sex and the 10 first PCs. After the 
association was adjusted for BMI (in addition to the aforementioned covariates), 
a somewhat lower but still significant estimate was still found (OR=1.11, 95% CI 
1.03 to 1.20, P=4.70×10−3), (Table 13).
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Table 13. Association between polygenic risk score (PRS) and obstructive sleep apnoea (OSA) in 
the UK Biobank
Model 1 Model 2
 OR 95% CI P OR 95% CI P
OSA_Q1 Reference Reference  
OSA_Q2 1.07 0.92-1.15 0.080 1.02 0.95-1.10 0.585
OSA_Q3 1.09 1.01-1.18 0.029 1.03 0.95-1.11 0.464
OSA_Q4 1.10 1.02-1.19 0.013 1.00 0.92-1.08 0.966
OSA_Q5 1.24 1.15-1.33 6.89x10-9 1.11 1.03-1.20 4.70x10-3
Model 1 is adjusted for age, sex and the 10 first principal components. Model 2 is adjusted for body 
mass index in addition to the covariates of Model 1. The OSA PRS was stratified into quintiles and 
OSA_Q5 is the highest quintile. OR=odds ratio, CI = 95% confidence interval. The table is adapted 
from the manuscript Strausz et al. (2020) Genetic analysis of obstructive sleep apnoea discovers 
a strong association with cardiometabolic health.
5.3.2 Gene based analyses
MAGMA was used in an exploratory analysis to annotate FinnGen OSA summary 
statistics based on 18 biological data repositories and tools (213). 25 significant 
associations (P<2.54×10−6) with various biological processes were detected, which 
were driven by the same loci as the significant GWAS variants in FTO and GAPVD1 
(Figure 8a). 
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Figure 8. a) Manhattan plot of the gene-based test as computed by multi-marker analysis of 
genomic annotation (MAGMA) using the OSA genome-wide association study (GWAS) data. Single 
nucleotide polymorphisms (SNPs) were mapped to 19,651 protein coding genes. A Bonferroni-
corrected significance threshold was defined as P =0.05/19,651=2.54×10−6. Primarily the same genes 
were identified as in the single variant associations. For each annotated gene, the x-axis shows the 
chromosomal position while the y-axis shows the −log10(P) value. EPHB2=Ephrin type-B receptor 
2, PCDHGA=Protocadherin gamma subfamily A, PCDHGB=Protocadherin gamma subfamily B, 
GAPVD1=GTPase activating protein and VPS9 domains 1, ASTN2= Astrotactin 2, GABBR2=Gamma-
aminobutyric acid type A receptor subunit 2, ANKS6=Ankyrin repeat and sterile alpha motif domain 
containing 6, DLEU7=Deleted in lymphocytic leukaemia 7, SCG3=Secretogranin III, FTO=Fat mass and 
obesity-associated protein, CLIC2=Chloride intracellular channel 2, BRCC3=BRCA1/BRCA2-containing 
complex subunit 3, MTCP1=Mature T cell proliferation 1, TMLHE=Trimethyllysine hydroxylase, epsilon, 
VBP1= VHL binding protein 1, RAB39B=RAB39B, member RAS oncogene family, FUNDC2=FUN14 
domain containing 2 and F8= Coagulation factor VIII. 
b) Manhattan plot of the gene-based test as computed by MAGMA using body mass index (BMI)-
adjusted GWAS data. SNPs were mapped to 19,651 protein coding genes. A Bonferroni-corrected 
significance threshold was defined as P=0.05/19,651=2.54×10−6. For each annotated gene the x-axis 
shows the chromosomal position while the y-axis shows the −log10(P) value. IQSEC1= IQ motif and 
sec7 domain arfGEF 1, SSPN=Sarcospan, PPP2R1A= Protein phosphatase 2 scaffold subunit aalpha. 
The figure is adapted from the manuscript Strausz et al. (2020) Genetic analysis of obstructive sleep 
apnoea discovers a strong association with cardiometabolic health.
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These may be potential target genes that associate with OSA, indicating that 
the genes could be relevant for OSA or OSA-associated comorbidities. The gene-
based test for BMI-adjusted OSA also revealed three further associated genes 
(Figure 8b).
5.3.3 Phenome-wide findings
A PheWAS was performed using FinnGen data to study the associations between 
the lead SNPs and 2,925 disease endpoints. Rs10507084 was again specific for OSA 
after adjustment for BMI. This suggests an association between rs10507084 and 
OSA independent of cardiometabolic traits (Figure 9a). FTO was associated with 
OSA, but also with a wide spectrum of cardiometabolic diagnoses as shown earlier 
(9, 214) and also to coffee consumption (217). The strongest PheWAS associations 
were observed with OSA-related diseases such as obesity (P=4.14×10−41), T2D 
(P=5.67×10−28) and hypertension (P=1.40×10−10).  In addition, there was a strong 
correlation between rs10507084 and the use of antidepressants (OR=1.013, 95% 
CI 1.007 to 1.019, P=4.4×10−6) (Figure 9b). This result remained significant after 
further adjustment for OSA diagnosis (OR=1.011, 95% CI 1.005 to 1.017, P=1.9×10−4).
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Figure 9. a) Phenome-wide association study (PheWAS) associations after body mass index (BMI) 
adjustment between rs10507084 and 2,925 disease endpoints. A Bonferroni-corrected significance 
threshold was defined as P = 0.05/2925 = 1.71 × 10−5. The vertical axis displays association P-values on 
the −log10 scale. Sleep apnoea refers to the validated disease endpoint. Primary health care diagnoses 
have not been validated. Sleep disorders, Episodal and paroxysmal disorders and Neurological 
diseases include sleep apnoea. The disease definition along the horizontal axis: 1. Certain infectious 
and parasitic diseases, 2. Neoplasms from hospital discharges , 3. Neoplasms, from cancer registry 
, 4. Diseases of the blood and blood-forming organs and certain disorders involving the immune 
mechanism, 5. Endocrine, nutritional and metabolic diseases, 6. Diabetes endpoints, 7. Mental and 
behavioural disorders, 8. Psychiatric endpoints, 9. Alcohol related diseases, 10. Diseases of the nervous 
system, 11. Neurological endpoints, 12. Diseases of the eye and adnexa, 13. Diseases of the ear and 
mastoid process, 14. Diseases of the circulatory system, 15. Cardiometabolic endpoints, 16. Diseases of 
the respiratory system, 17. Asthma and related endpoints, 18. Chronic obstructive pulmonary disease 
and related endpoints, 19. Interstitial lung disease endpoints, 20. Diseases of the digestive system, 
21. Dental endpoints, 22. Gastrointestinal endpoints, 23. Diseases of the skin and subcutaneous 
tissue, 24. Diseases of the musculoskeletal system and connective tissue, 25. Rheumatoid arthritis 
endpoints, 26. Diseases of the genitourinary system, 27. Pregnancy, childbirth and the puerperium , 
28. Certain conditions originating in the perinatal period, 29. Congenital malformations, deformations 
and chromosomal abnormalities, 30. Symptoms, signs and abnormal clinical and laboratory findings, 
not elsewhere classified, 31. Injury, poisoning and certain other consequences of external causes, 
32. External causes of morbidity and mortality, 33. Factors influencing health status and contact 
with health services, 34. Drug purchase endpoints, 35. Diseases marked as autoimmune origin, 
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36. Common endpoint, 37. Demonstration endpoints, 38. ICD-10 main chapters, 39. Operation 
endpoints, 40. Other, not yet classified endpoints, 41. Miscellaneous, not yet classified endpoints, 
42. Comorbidities of Asthma, 43. Comorbidities of Chronic obstructive pulmonary disease, 44. 
Comorbidities of Diabetes, 45. Comorbidities of Gastrointestinal endpoints, 46. Comorbidities of 
Interstitial lung disease endpoints, 47. Comorbidities of Neurological endpoints, 48. Comorbidities 
of Rheumatoid arthritis endpoints
b) PheWAS analysis concerning drug purchases. The x-axis shows phenotypes based on Anatomical 
Therapeutic Chemical System (ATC) drug codes, while  the y-axis shows the Bonferroni-corrected 
significance threshold (0.05/69 = 7.25 × 10−4 ) -log10(P) values. Drugs were coded as continuous 
variables and inverse normalized to ensure normal distribution for analysis. Other antidepressant=ATC 
N06AX, Hypnotics and sedatives=ATC N05C, Psycholeptics=ATC N05, Antidepressants=ATC N06A, 
Cycclopyrrolones=ATC N05CF, Antipsychotics=ATC N05A. The figure is adapted from the manuscript 
Strausz et al. (2020) Genetic analysis of obstructive sleep apnoea discovers a strong association with 
cardiometabolic health.
An association near RMST/NEDD1 was specific for OSA independent of BMI. 
The lead SNP was associated with antidepressant purchases, which connects this 
locus with the regulation of sleep and mood. The finding may also reflect the 
earlier observation that depression is prevalent among patients with OSA (100).
5.3.4 Genetic correlations and Mendelian randomization
The potential genetic associations between OSA and its known epidemiological 
correlates were studied using FinnGen summary statistics to calculate genetic 
correlations. Strong genetic correlations between OSA and BMI (rg =0.72, 95% CI 
0.62 to 0.83, P=3.49×10−40) and between OSA and other OSA-related comorbidities 
were found: hypertension (rg=0.35, 95% CI 0.23 to 0.48, P=4.06×10−8), T2D 
(rg =0.52. 95% CI 0.37 to 0.66, P=6.40×10−12), CHD (rg =0.38, 95% CI 0.17 to 0.58, 
P=3.84×10−4), stroke (rg =0.33, 95% CI 0.03 to 0.63, P=2.93×10−2), depression 
(rg =0.43, 95% CI 0.27 to 0.60, P=2.79×10−7), hypothyroidism (rg =0.40, 95% CI 
0.27 to 0.54, P=7.07×10−9), asthma (rg =0.50, 95% CI 0.33 to 0.68, P=1.53×10−8) 
and IRD (rg =0.34, 95% CI 0.09 to 0.58, P=6.97×10−3). Additionally, high genetic 
correlations between OSA-related comorbidities were observed. Since many 
OSA comorbidities are associated with BMI, the genetic correlations were then 
calculated after BMI adjustment. This analysis showed somewhat lower estimates 
for genetic correlations between OSA and CHD (rg =0.24 95% CI 0.012 to 0.47, 
P=0.04), depression (rg =0.33, 95% CI 0.17 to 0.50, P=1.1×10−3), asthma (rg =0.33, 
95% CI 0.11 to 0.54, P=2.6×10−3) and hypothyroidism, (rg =0.28, 95% CI 0.11 to 
0.44, P=8.0×10−4). Genetic correlations between OSA and BMI (rg =0.08, 95% CI 
-0.05 to 0.22, P=0.22), hypertension (rg =0.05, 95% CI -0.10 to 0.20, P=0.51), T2D 
(rg =0.15, 95% CI -0.03 to 0.33, P=0.11), stroke (rg =0.32, 95% CI -0.05 to 0.69, 
P=0.09) and IRD (rg =0.27, 95% CI -0.01 to 0.54, P=5.7×10−2) were attenuated 
after BMI adjustment (Figure 10). The estimate showed a strong positive genetic 
correlation between males and females (rg =1, 95% CI 1.15 to 0.85), P=1.85×10−12). 
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Figure 10. Genetic correlations between obstructive sleep apnoea (OSA), body mass index (BMI) 
and previously known OSA-related comorbidities using linkage disequilibrium score regression. The 
colour-scale represents the strength of the correlation. Correlations between OSA and other traits 
have been calculated with and without BMI-adjustment. CHD=coronary heart disease, T2D=type 
2 diabetes, IRD=inflammatory rheumatic diseases. The figure is reproduced from the manuscript 
Strausz et al. (2020) Genetic analysis of obstructive sleep apnoea discovers a strong association with 
cardiometabolic health.
UKBB-derived summary statistics for sleep traits and the FinnGen OSA 
summary statistics were used to estimate genetic correlations of sleep traits. 
Genetic correlations were observed with snoring (207) (rg=0.81, 95% CI 0.69 to 0.93, 
P=1.24×10−38), sleep efficiency (210) =-0.31, 95% CI -0.44 to -0.17, P=9.80×10−6) 
and daytime sleepiness (208) (rg =0.44, 95% CI 0.33 to 0.54, P=1.27×10−15). These 
associations remained significant also after BMI adjustment (rg =0.68, 95% CI 
0.55 to 0.81, P=2.93×10−26, rg =-0.19, 95% CI -0.36 to -0.03, P=0.02, rg =0.42, 95% 
CI 0.29 to 0.55, P=1.06×10−10, respectively). No significant genetic correlations 
between OSA and sleep duration or chronotype were noted (209), (Table 14). 
The causal relationship between OSA and its comorbidities was tested by 
analysing OSA PRSes followed by MR analysis using FinnGen OSA summary 
statistics and independent BMI SNPs (9). A strong association with OSA risk was 
found and the individuals in the highest BMI PRS quintile had 1.98-fold increased 
(95% CI 1.88 to 2.09, P=3.38×10−140) OSA risk after adjusting for age, sex and the 
10 first PCs. This association was further confirmed in formal MR analysis. Sixty-
four independent BMI SNPs (9) were used as genetic instruments to predict OSA. 
In line with former epidemiological studies and the genetic correlation results, a 
strong causal effect from BMI to OSA was discovered (Inverse variance weighted 
beta=0.67, P=8.32×10−16), (Figure 11). 
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Table 14. Genetic correlations between obstructive sleep apnoea (OSA) and other sleep traits




OSA rg = 0.81 
[0.69-0.93] 
P = 1.24 × 10−38
rg = 0.44 
[0.33-0.54]
P = 1.27 × 10-15
rg = 0.01 
[-0.09-0.10] 
P = 0.84
rg = -5.0 × 10−4 
[-0.08-0.08]
P = 0.99






*rg = 0.68 
[0.55-0.81) 
P = 2.93 × 10−26
rg = 0.42 
[0.29-0.55]
P = 1.06 × 10-10
rg = 0.08 
[-0.03-0.19] 
P = 0.14
rg = -0.06 
[-0.15-0.03] 
P = 0.18
rg = -0.19 
[-0.36 - -0.03]
P = 0.02
Summary statistics for sleep traits that were used to calculate the genetic correlations were obtained 
from previous genome-wide association studies (GWASes) from the UK Biobank. *GWAS for snoring 
was also body mass index (BMI)-adjusted. [95% confidence interval]. The table is adapted from 
the manuscript Strausz et al. (2020) Genetic analysis of obstructive sleep apnoea discovers a strong 
association with cardiometabolic health.
Figure 11. Formal Mendelian randomization (MR) analysis suggesting a strong causal relationship 
between body mass index (BMI) and obstructive sleep apnoea (OSA) where BMI predicts OSA as 
an outcome. The figure is reproduced from the manuscript Strausz et al. (2020) Genetic analysis of 
obstructive sleep apnoea discovers a strong association with cardiometabolic health.
Biological mechanisms of OSA were also examined through partitioned tissue 
enrichment analysis using LDSC, which combines data from the ENCODE and 
GTEx resources (211, 212) with FinnGen OSA summary statistics. The strongest 
association was with cardiovascular tissues and connective and bone tissues 
(P<0.05). Furthermore, enrichment in BMI-adjusted OSA results suggested the 
central nervous system as the strongest single-tissue association when a nominal 
significance level of P=0.05 is used (Figure 12). 
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Figure 12. Tissue-specific enrichment analysis. Stratified linkage disequilibrium (LD) score regression 
was performed based on the 1000 Genomes Project phase 1 single nucleotide polymorphisms. LD 
was calculated for each tissue type. Each bar represents the -log10 P-value for enrichment and was 
computed for obstructive sleep apnoea (OSA) and body mass index (BMI)-adjusted OSA.  CNS=central 
nervous system, GI=gastrointestinal. The figure is adapted from the manuscript Strausz et al. (2020) 
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health.
5.4 Obstructive sleep apnoea as a risk  
factor for COVID-19
5.4.1 Findings in FinnGen
Mild OSA cases are not usually referred to secondary health care. Therefore, in 
our data the majority of the OSA individuals have a moderate or severe form of the 
disease. Our study also included 445 individuals with a PCR-validated COVID-19 
diagnosis (37.3% male, mean age 52.7 years). Of these individuals, thirty-eight 
patients also had an OSA diagnosis (8.5%, 50.0% male, mean age 61.3 years), 
(Table 15, Table 16). The prevalence of OSA among COVID-19 patients is similar 
to the normal population in FinnGen, where the prevalence is 7.7%. Altogether, 
91 (20.4%) patients required hospitalisation (36.3% male, mean age 65.9 years) 
including nineteen OSA patients (Table 15). 
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Table 15. Comparison of the baseline characteristics in hospitalised and non-hospitalised COVID-19 









Age (mean in years, SD) 52.7 (17.4) 49.3 (16.3) 65.9 (14.8) 1.06×10-15
Sex (male) (N, %) 166 (37.3) 133 (37.6) 33 (36.3) 1
OSA (N, %) 38 (8.5) 19 (5.4) 19 (20.9) 5.13×10-5
BMI (mean kg/m2, SD) 27.13 (5.44) 26.54 (5.2) 29.25 (5.8) 0.014
Hypertension (N, %) 79 (17.8) 40 (11.3) 39 (42.9) 5.03×10-11
Diabetes (N, %) 46 (10.3) 23 (6.5) 23 (25.3) 3.45×10-6
CHD (N, %) 21 (4.7) 9 (2.5) 12 (13.2) 5.20×10-4
Asthma/COPD (N, %) 54 (12.1) 40 (11.3) 14 (15.4) 1
Differences and associations between non-hospitalised and hospitalised COVID-19 patients. Statistics 
for baseline demographics and clinical characteristics (Punadjusted ) were based on the X2 test. For 
continuous variables, we used Student’s t-tests. Body mass index (BMI) was measured for 264 
participants, including 206 non-hospitalised and 58 hospitalised individuals. OSA=obstructive sleep 
apnoea, CHD=coronary heart disease, COPD=chronic obstructive pulmonary disease, SD=standard 
deviation. The table is adapted from Strausz et al. (2020) Sleep apnoea is a risk factor for severe 
COVID-19.
The prevalences of OSA (P=5.13×10−5), hypertension (P=5.03×10−11), diabetes 
(P=3.45×10−6) and CHD (p=5.20×10−4) were higher in the hospitalised group. 
Similarly, age and BMI were higher among hospitalised individuals (P=1.06×10-15, 
P=0.014, respectively), (Table 15). 
The main risk factors between COVID-19 patients with OSA (N=38) and 
those who did not have an OSA diagnosis (N=407) were compared. OSA patients 
were older, and their BMI was higher (mean age 61.3 years, BMI 31.15 kg/m2, 
P=5.60×10−4, P=3.38×10−3, respectively) than non-OSA individuals (mean age 51.9 
years, BMI 26.71 kg/m2). Also, comorbidities were more prevalent among OSA 
individuals (P=1.74×10−4) and they faced hospitalisation more often (P=3.21×10−5). 
No differences were observed in risk factors when comparing non-hospitalised 
(N=19, male 63.2%, mean age 56.3 years) and hospitalised OSA patients (N=19, 
male 36.8%, mean age 66.3 years), (Table 16). In addition, seven out of nineteen 
patients with OSA who were hospitalised due to COVID-19 did not have any other 
disease comorbidities. No significant differences concerning age or BMI were noted 
between individuals who had only OSA as a comorbidity or also other comorbidities 
in addition to OSA (62.8 years, 68.9 years, P=0.72, 30.26 kg/m2, 32.67 kg/m2, P=1.00, 
respectively). 
The time from first OSA diagnosis to COVID-19 infection was not significantly 
different between non-hospitalised and hospitalised groups (6.6 years, 8.6 years, 
P=0.37, respectively). 
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Table 16. Description of COVID-19 patients with or without obstructive sleep apnoea (OSA) and a 














(mean in years, SD)
51.9 (17.5) 61.3 (12.9) 5.60×10-4 56.3 (11.0) 66.3 (12.9) 0.057
Sex (male) (N, %) 147 (36.1) 19 (50.0) 0.645 12 (63.2) 7 (36.8) 0.776
BMI  
(mean kg/m2, SD)
26.71 (5.27) 31.15 (5.56) 3.38×10-3 30.91 (5.58) 31.37 (5.77) 1
Comorbidities or 
outcomes (N, %) 
118 (29.0) 24 (63.2) 1.74×10-4 12 (63.2.) 12 (63.2) 1
Hospitalised  
(N, %)
72 (17.7) 19 (50.0) 3.21×10-5
Differences between non-OSA vs. OSA and non-hospitalised OSA patients vs. hospitalised OSA 
patients among COVID-19-diagnosed individuals. 7/19 patients who were hospitalised had an OSA 
diagnosis but did not have any other disease comorbidities. P-values were based on X2 tests. Fisher’s 
exact test was used if the sample size was ≤ 5. For continuous variables, we used Student’s t-tests. 
BMI was measured for 264 participants including 239 non-OSA and 25 OSA individuals. BMI=body 
mass index, Comorbidities or outcomes=hypertension, diabetes, coronary heart disease, asthma, 
chronic obstructive pulmonary disease, SD=standard deviation. The table is adapted from Strausz 
et al. (2020) Sleep apnoea is a risk factor for severe COVID-19.
The risk for COVID-19 diagnosis in general (N=445) or severe COVID-19 
disease, determined as being hospitalised (N=91), was tested for association 
with OSA. The models were adjusted for age, sex, BMI, hypertension, diabetes, 
CHD, asthma and COPD. OSA patients had a considerably elevated risk for being 
hospitalised due to severe COVID-19 (OR=2.93, 95% CI 1.02 to 8.13, P=0.045), 
(Table 17). OSA did not affect the risk of contracting COVID-19 (P=0.25).
Table 17. Association between obstructive sleep apnoea and severe COVID-19
OR [95 CI] P
Model 1 3.85 [1.82-8.13] 4.13×10-4
Model 2 3.45 [1.27-9.35] 0.016
Model 3 2.93 [1.02-8.39] 0.045
Model 1 is adjusted for age and sex. Model 2 is adjusted for body mass index (BMI) in addition 
to the covariates of Model 1. Model 3 is adjusted for BMI, hypertension, diabetes, coronary heart 
disease, asthma and chronic obstructive pulmonary disease in addition to the covariates of Model 
1. OR=odds ratio, CI=confidence interval. The table is adapted from Strausz et al. (2020) Sleep 
apnoea is a risk factor for severe COVID-19.
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To investigate the OSA patients diagnosed with COVID-19 in more detail, 
we assessed the health care data of 305 COVID-19 patients (including eleven 
patients also diagnosed with OSA) who were treated in Heart and Lung Centre 
or Department of Oral and Maxillofacial Diseases, HUH, Finland by the end 
of October 2020. Nine out of eleven had severe OSA and two out of eleven had 
moderate OSA. Eight out of eleven had treated OSA; seven patients had CPAP 
therapy and one patient had MAD. Prior to COVID-19 diagnosis, CPAP-treated 
patients used their appliances 98% of nights with a 6.3 hours mean time used and 
mean AHI during CPAP treatment was 1.86 events / hour. Despite OSA treatment 
maintenance, all eleven patients required hospital treatment for either pneumonia 
or other COVID-19 symptoms, such as high fever. All patients needed non-invasive 
ventilation support and two required intubation. Mean treatment time in hospital 
was 15 days. More specific patient characteristics are presented in Table 18. 
Table 18. Health care data characteristics of obstructive sleep apnoea individuals diagnosed with 
COVID-19
N=11
Age (mean in years, SD) 55.1 (8.0)
Sex (male) (N, %) 9 (81.8)
BMI (mean kg/m2, SD) 35.08 (5.96)
Diabetes (N, %) 3 (27.3)
Hypertension (N, %) 7 (63.6)
CHD (N, %) 3 (27.3)
CPAP (N, %) 7 (63.6)
MAD (N, %) 1 (9.1)
AHI (mean, SD) 43.3 (20.6)
ODI3 or 4 (mean, SD) 39.6 (15.7)
Sp02 mean (mean, SD) 91.0 (3.3)
Sp02 min (mean, SD) 79.4 (8.3)
AHI with CPAP (mean, SD) 1.86 (2.07)
ICU (N, %) 3 (27.3)
NIV (N, %) 11 (100)
Intubation (N, %) 2 (18.2)
Treatment time in hospital 
(mean in days, SD)
15 (8.6)
BMI=body mass index, CHD=coronary heart disease, CPAP=continuous positive airway pressure, 
MAD=mandibular advancement device, AHI=apnoea-hypopnoea-index, ODI 3 or 4=oxygen desaturation 
index; the number of times per hour of sleep that the blood's oxygen level drop 3 or 4 percent 
from the baseline, SpO2=oxygen saturation, ICU=intensive care unit, NIV=non-invasive ventilation, 




Using our results and the results of previous studies (16-18), a random effect meta-
analysis using REML estimation was used to further investigate the role of OSA 
on COVID-19. This meta-analysis included 15,835 COVID-19 positive individuals 
with 1,294 OSA patients and showed an over two-fold increase in the risk for 
hospitalisation for COVID-19 with a previous OSA diagnosis (OR=2.37, 95% CI 
1.14 to 4.95, P=0.021). Adjusted estimates were available in the study of Cade et 
al. 2020 (BMI) and Maas et al. 2020 (BMI, hypertension and diabetes) but not 
in the study of Cariou et al. 2020 (16-18). The risk became non-significant after 
adjustment for BMI (OR=1.55, 95% CI 0.88 to 2.72, P=0.13), (Figure 13).  
Figure 13. Forest plots of obstructive sleep apnoea and the risk of hospitalisation due to COVID-19. The 
evidence was combined using random-effect meta-analysis. The data consisted of 15,835 COVID-19 
patients including 1,294 patients with a prior OSA diagnosis. A) The model is adjusted for age and 
sex, and ethnic background if available. *The Cariou et al. study’s primary outcome was defined 
as tracheal intubation and/or death within 7 days of admission. b) The model is adjusted for age, 
sex, and BMI. ** The Maas et al. study is adjusted for diabetes and hypertension in addition to the 
aforementioned covariates. The figure is adapted from Strausz et al. (2020) Sleep apnoea is a risk 
factor for severe COVID-19.
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6 DISCUSSION
In general, OSA is strongly associated with cardiometabolic health. As OSA 
research has been so far lacking large genetic studies, we were able to show for 
the first time a causal relationship between obesity and OSA by MR analysis. This 
confirms the findings which have been seen previously through epidemiological 
studies. Additionally, our findings concerning the association between OSA and 
COVID-19 show that the issues of OSA treatment and diagnosis are particularly 
topical.  
The genetics of OSA have been largely unexplored. Common complex 
genetic diseases such as OSA do not follow Mendelian patterns of inheritance 
and characteristically involve many genes that interact with environmental factors. 
Determining these genes has been challenging prior to the widespread use of the 
GWAS method. For current analyses, large biobank data sets need to be utilized 
and combined with phenotype data. In addition, the development of sophisticated 
statistical methods has allowed cost-effective and accurate analyses of samples 
and data. The FinnGen project combines these features and has enabled our study 
of the genetics of OSA. 
6.1 Obstructive sleep apnoea diagnosis has excellent 
validity
OSA diagnosis in the Finnish healthcare context has a validity of over 98% PPV. 
The interpretation of this finding is that Finnish registries capture OSA patients 
well and therefore provide a powerful and cost-effective tool to collect and utilize 
data for research use.  Indeed, the studies included in this thesis are based on the 
fact that the OSA diagnosis is reliable, which provides a comprehensive basis for 
research. Overall, the registries combined into the FinnGen project have very good 
validity and coverage (218, 219). These findings further reinforce the evidence of 
the quality of our data as we study apnoea both genetically and epidemiologically. 
6.2 Obstructive sleep apnoea is a risk factor for 
cardiometabolic outcomes
A large-scale population-based cohort study was utilized that includes up to 25 
years of follow-up and over 500,000 person-years. The results are well in line 
with previous studies concerning OSA as a risk factor for CHD, but differences 
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also exist. Additionally, women with OSA were at an elevated risk for CHD and 
T2D which has not been consistently seen in previous studies. 
There are several potential explanations for this discrepancy, such as the 
fact that OSA has traditionally been categorized as a men’s disease and less 
attention has been paid to women when making a diagnosis of OSA. This may 
have caused power problems in previous analyses. Similarly, disease definitions 
that define hypopnoeas as ≥4% ODI underestimate AHI in women, who may have 
more hypopnoeas than obstructions, suggesting that OSA could be more severe 
in women than polysomnography results show (220).   
Among diabetic patients it is increasingly recognized that OSA can accelerate 
the loss of kidney function, potentially through oxidative stress, hypoxemia, 
and endothelial dysfunction (98). As this association is also hypothesized to be 
bidirectional, many studies support the finding that OSA worsens kidney function. 
As OSA is remarkably common among T2D patients, it should be investigated in 
individuals who also have T2D in their disease burden (97, 98). 
A previous meta-analysis concerning OSA and mortality showed that severe 
OSA is associated significantly with mortality risk (92). In our study, this risk was 
increased only among the T2D patient population. One reason for this somewhat 
different result could be that our OSA patients are mostly well managed, as the 
diagnoses are derived from secondary health care records and the majority of 
patients have hence received either CPAP or MAD therapy and conservative 
treatment (221).   
An additional important finding is that OSA with insomnia is more common 
in women than in men (222).  Despite lower AHI, insomniac patients have a higher 
burden of cardiovascular, pulmonary and psychiatric comorbidities and a lower 
CPAP adherence compared to patients without insomnia symptoms (223).
6.3 Genetics of obstructive sleep apnoea correlates 
strongly with cardiovascular and metabolic traits
Biobank data comprised of over 217,000 participants was used to study the genetics 
behind OSA. A strong genetic predisposition for OSA was shown, identified by five 
genetic loci. High genetic correlations between OSA and cardiometabolic diseases 
and other comorbidities were found, with the strongest connections between OSA 
and BMI, hypertension, T2D and CHD, further supporting earlier epidemiological 
findings. In addition, the PRS and MR results support a causal role for obesity 
in OSA. 
Several conclusions can be drawn based on these results, which represent the 
first reported case-control GWAS of OSA. First, genetic variation has a significant 
contribution to the development of OSA. This is supported by both SNP-based 
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heritability estimates and the significantly associated loci from the GWAS analysis. 
Second, the results support the fact that obesity has a central, causal role in OSA. 
This is supported by the fact that four out of five of our OSA-associated genetic 
loci were mediated through their associations with BMI. These results are in line 
with the finding that weight loss is an important contributor to lower AHI. A 10% 
weight gain increases AHI 32% and correspondingly a 10% decrease in weight has 
been associated with a 26% decrease in AHI (65). Third, an OSA association near 
RMST/NEDD1, which was specific for OSA independent of BMI, was identified. 
The lead SNP could not be replicated in independent cohorts, but it was associated 
with antidepressant purchases, suggesting a connection between this locus and the 
regulation of sleep and mood. This finding may also reflect the earlier observation 
that depression is prevalent among patients with OSA (100).  Fourth, a strong 
genetic correlation was observed between OSA and sleep traits, especially with 
sleepiness and sleep efficiency. This finding highlights the pathological effects of 
OSA on sleep. 
As OSA and its associated diseases seem to share a common genetic basis, 
both CPAP and MAD treatments have numerous positive health effects not only 
for OSA but also for its comorbidities through e.g., lowering blood pressure and 
improving sleep-related symptoms as well as the quality of life, creating a virtuous 
cycle. Therefore, our genetic correlations also emphasize the importance of treating 
OSA.
6.4 Obstructive sleep apnoea is a risk factor for severe 
COVID-19
The role of OSA as a risk factor for COVID-19 leading to hospitalisation was studied, 
revealing a higher risk for a hospitalisation in patients with moderate or severe OSA, 
independent of BMI and other known risk factors for OSA or severe COVID-19. 
This finding is comparable to the risk among individuals with diabetes, where an 
elevated risk has been previously reported for severe COVID-19 (224). 
There are several potential explanations for how OSA may predispose to 
severe COVID-19. Individuals with OSA often have one or more comorbidities 
that are known risk factors for severe COVID-19. For example, high BMI increases 
the risk for severe COVID-19. Additionally, OSA may exacerbate the symptoms 
of severe COVID-19 as decreased oxygen saturation levels occur in OSA during 
sleep (5). 
Treatment information concerning OSA patients who had contracted 
COVID-19 was also collected. This revealed the fact that despite good management 
of OSA, patients with moderate or severe OSA were more likely to develop a 
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severe form of COVID-19. All OSA patients required hospital care, suggesting 
that moderate or severe OSA is a risk factor even if well treated.
Based on our results and the results of previous studies (16-18), a meta-
analysis was carried out to increase the knowledge of the role of OSA on COVID-19 
hospitalisation. Our meta-analysis suggested OSA is a risk factor and showed an 
association of over 2-fold increased risk related to COVID-19 hospitalisation, but 
after BMI-adjustment the result of the meta-analysis became non-significant. This 
suggests confirmation of the known fact that obese individuals have an increased 
risk for the severe form of COVID-19. 
The findings based on our report are in line with previous studies on COVID-19 
comorbidities and OSA, regardless of slightly different endpoint definitions 
(contracting COVID-19, severity of the disease, mechanical ventilation, and death). 
Concordantly all studies showed a significant association with COVID-19 severity 
and OSA (16-18) but differences also existed. Only one study showed a statistically 
significant association between OSA and severe COVID-19 after adjusting for BMI 
(18). These findings indicate that while OSA is an expected a risk factor for severe 
COVID-19 disease, evaluating the magnitude of this association would benefit from 
harmonized analyses across different cohorts where comorbidities and disease 
endpoints are similarly assessed.
Our findings, together with earlier reports, suggest that OSA should be taken 
into account when assessing the risk of developing life-threatening complications 
of COVID-19, paying special attention to individuals with moderate or severe OSA. 
6.5 Strengths
Accurately-defined OSA diagnoses are the core of the registry-based studies in 
this thesis. Here we are able to show that the diagnosis has excellent validity, 
which reinforces the utilization of the diagnosis derived from Hospital Discharge 
and Causes of death registries in these studies. The main strength of this work is 
the large and comprehensively collected data that also include a long follow-up, 
reaching up to 25 years and including over 500,000 person-years. The FinnGen 
project combines registry data with genotype data and thus creates a unique 
environment to study common complex diseases, such as OSA. 
6.6 Limitations 
The studies introduced in this thesis do have some limitations. First, registry-based 
ascertainment through hospitalisation may miss non-hospitalised cases (false 
negatives) and treatment information such as CPAP compliance or MAD usage is 
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missing from the data. The validation study was performed using data from only 
one hospital district, which does not guarantee that the data is as consistent in 
other parts of the country. However, HUS is the largest hospital district and the 
majority of the patients in the study were from that area. Second, in Study II, due to 
a relatively small number of cases in the replication datasets, our statistical power 
was limited in the replication analysis. Additionally, the finding of rs185932673 
should be interpreted cautiously as the variant is rare in the Finnish population 
and the association was not replicated in the other study samples. In Study III, a 
relatively small number of individuals have had COVID-19 during the first wave 
of the disease in Finland. Therefore, because of the relatively small sample size, 
the confidence intervals are relatively large.
6.7 Impact and generalizability 
The epidemiology of OSA has been extensively studied and its effects on health 
and related comorbidities are fairly well known. However, the genetics of OSA has 
been largely unstudied. Here we present results utilizing nationwide registries 
and biobank data to show that genetic variation plays an important role in the 
development of OSA, and this association is primarily mediated through BMI. 
In addition, OSA is both epidemiologically and genetically associated with its 
comorbidities, indicating that OSA is a heterogenic disease with several distinct 
comorbidities. This would be beneficial to consider when treating patients with 
OSA. 
During this exceptional pandemic time, we have created more knowledge 
concerning OSA as a risk factor for severe COVID-19. Therefore, in the assessment 
of patients with a suspected or confirmed COVID-19 diagnosis, OSA should be 
recognised as one of the risk factors for developing a severe form of the disease. 
6.8 Future research 
As OSA is a very common disease including many, even life-threatening, adverse 
effects, attention should be paid not only to treatment guidance and identification 
of OSA and its comorbidities, but also to prevention. In addition, large datasets 
with genetic information may allow identification of even more accurate disease 
patterns, creating opportunities to study the genetics underlying craniofacial traits. 
These features provide information concerning an individual’s genetic OSA risk 
and possibly individualized prevention strategies and treatments.
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7 CONCLUSIONS 
I. After adjusting for conventional cardiovascular disease risk factors, 
obstructive sleep apnoea (OSA) was a risk factor for coronary heart disease 
(CHD), type 2 diabetes (T2D) and notably for diabetic kidney disease (DKD). 
OSA also increased the risk for mortality among the T2D population. The 
association between OSA, CHD and T2D risk was also elevated in women, 
who have traditionally received less attention in the diagnosis and treatment 
of OSA than men.  These findings emphasize the need to search for signs of 
OSA also in women, and in patients with T2D.
II. Our findings highlight the causal links between obesity and OSA but also 
provide possible evidence for non-body mass index (BMI)-dependent genetic 
effects. In addition to BMI, we show that genetic effects that modify the 
risk of cardiometabolic diseases, depression, hypothyroidism, asthma and 
inflammatory rheumatic diseases (IRD) are also correlated with the genetic 
effects for OSA. This shows that the observed comorbidities between OSA 
and these diseases may have a joint genetic basis. 
III. Our results support the fact that OSA is a heterogenic disease with several 
distinct comorbidities, which would be beneficial to consider when treating 
patients with OSA.
IV. Patients with moderate or severe OSA had 2.93 times higher risk of 
hospitalisation when diagnosed with COVID-19 than non-OSA individuals. 
Our findings may suggest that, in the assessment of patients with suspected 
or confirmed COVID-19, OSA should be recognized as one of the risk factors 
for developing a severe form of the disease. 
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